       
201209135 – Protocol Clarification Letter, 01 October 2020  
 
 
Protocol Administrative Letter  
 October 1, 2020  
 “A Phase II Study of Neratinib Alone and in Combination with Fulvestrant  in Metastatic 
HER2 Non -amplified but HER2 Mutant Breast Cancer ” 
 
The purpose of this letter is to clarify an error regarding the duration of follow -up after the last 
dose of protocol therapy.  In Protocol Amendment 13.0, 16MAR2020, Section 6.[ADDRESS_544949] me or the regulatory coordinator ( Natalie Benford at 
[EMAIL_8207]
, 314- 747-8365)  
 
 
Regar ds, 
 [CONTACT_206007] , MD, PhD. 
Professor  of Medicine  
Washington University School of Medicine  
Internal Medicine – Medical Oncology 
Phone: 314- 362-8903 
Email
: [EMAIL_4038]  
  
Version 03/16/2020 – Amendment [ADDRESS_544950] Cancer   
 
Protocol#:  201209135  
Version date: 03/16/2020  
 
Coordinating Center:   Washington University School of Medicine  
[ADDRESS_544951]. Louis, MO [ZIP_CODE]  
 
Principal Investigator:   [INVESTIGATOR_171706] X. Ma , M.D., Ph.D. 
    Washington University School of Medicine  
     Telephone: [PHONE_8959]  
     Email: [EMAIL_4038]  
 
 
Sub-Investigators:   Institution:      Division:  
Matthew J.C. Ellis, M.B., Ph.D.  Baylor College of Medicine    Medical Oncology  
Ron Bose, M.D., Ph.D.   Washington University     Medical Oncology  
Carey  Anders, M.D.   Lineberger Cancer Center    Medical Oncology  
Rachel Freedman , M.D.   Dana Farber Cancer Institute   Medical Oncology  
Philippe Bedard, M.D.   Princess Margaret Cancer Centre   Medical Oncology  
Kimberly Blackwell, M.D.   Duke Cancer Institute    Medical Oncology  
Melody Cobleigh, M.D.    Rush University Medical Center    Medical Oncology  
Andres Forero, M.D.    University of Alabama     Medical Oncology  
Daniel Hayes, M.D.    University of Michigan     Medical Onco logy 
Janice Lu , M.D.    University of Southern [LOCATION_004]   Medical Oncology  
Mark Pegram, M.D.    Stanford Medicine Cancer Institute  Medical Oncology  
Timothy J. Pluard, M.D.    St. Luke’s Cancer Institute    Medical Oncology  
Matthew Goetz, M.D.    Mayo Clinic      Medical Oncology  
Julie Nangia, M.D.   Baylor College of Medicine    Medical Oncology  
Jason Jones, M.D.   Avera Cancer Institute    Medical Oncology  
Marc E. Lippman, M.D.   University of Miami     Medical Oncology  
Massimo Cristofanilli, M.D.   North western  University    Medical Oncology  
Foluso Ademuyiwa, M.D.   Washington University    Medical Oncology  
Michael J. Naughton, M.D.   Washington University    Medical Oncology  
Rama Suresh, M.D.    Washington University    Medical Oncology  
Leonel Hernandez-Aya, M.D.   Washington University    Medical Oncology  
Katherine Weilbaecher, M.D.   Washington University    Medical Oncology  
Ashley Frith, M.D.   Washington Univer sity    Medical Oncology   
Haeseong Park, M.D.    Washington University    Medical Oncology  
Matthew Cherian, M.D.   Washington University    Medical Oncology  
Lindsay Peterson, M.D.     Washington University    Medical Oncology  
Feng Gao, M.D., Ph.D.   Washington University    Biostatistics  
 
Washington University Research Coordinator 
Caroline Bumb  
Telephone: 314-362 -7249  
Email: [EMAIL_8208]  
 

  
Version 03/16/2020 – Amendment [ADDRESS_544952] Cancer   
 
Study Drug(s): Neratinib ( PB-272)  
IND#: 116297 // Clinical Trials.gov#: [STUDY_ID_REMOVED] 
 
 
Protocol Revision History  
 
Initial Approval Version         09/27/12  
Amendment #1          01/02/13  
Amendment #2          03/22/13  
Amendment #3          04/22/13  
Amendment #4          09/04/13  
Amendment #5          11/08/13  
Amendment #6          12/26/13  
Amendment #7          02/05/15  
Amendment #8          12/11/15  
Amendment #9                                                                                                09/14/16  
Amendment #10          02/07/17  
Amendment #11          10/05/17  
Amendment #12          06/15/18  
Amendment #13          03/16/2020  
 
      
          
          
  
Version 03/16/2020 – Amendment [ADDRESS_544953] Cancer  
 
 
Principal Investigator [INVESTIGATOR_430887]:   Cynthia X. Ma , M.D. , Ph.D.  
 
   
 Signature [CONTACT_295839] [CONTACT_27616], I agree to personally supervise the 
conduct of this study and to ensure its conduct in compliance with the protocol, informed consent, IRB/HRPO procedures, the Declaration of Helsinki, ICH Good Clinical Practices guidelines, and the applicable parts of the [LOCATION_002] Code of Federal Regulations or local regulations governing the conduct of clinical 
studies.  
   
  
  
Version 03/16/2020 – Amendment [ADDRESS_544954] Information  
  
Ron Bose, M.D., Ph.D.  
Washington University School of Medicine  
Telephone: 314-747 -9308  
Email: [EMAIL_6587]   
   
Matthew J. Ellis, M.B., Ph.D.  
Baylor College of Medicine  
Email: [EMAIL_8209]   
 
 
Rachel Freedman, M.D. 
Dana-Farber Cancer Institute 
Harvard University  
Email: [EMAIL_8210]   
 Carey  Anders , M.D.  
Lineberger Comprehensive Cancer Center  
University of North Carolina at Chapel Hill Email: [EMAIL_8211]
 
 
Timothy Pluard, M.D. 
St. Luke’s Cancer Institute  
Email: tpluard@saint -lukes.org  
 
Kimberly Blackwell, M.D.  
Duke Cancer Institute 
Duke University Medical Center  
Email: [EMAIL_8212]  
 Melody Cobleigh, M.D.  
Rush University Medical Center  
Email: [EMAIL_8213]   
Janice Lu, M.D.  
Keck School of Medicine  
University of Southern [LOCATION_004]  
Email: Janice.Lu @med.usc.edu  
 Andres Forero, M.D.  
University of Alabama Cancer Center  
Email: [EMAIL_8214]   
Philippe Bedard, M.D.  
Princess Margaret Cancer Centre  
Email: [EMAIL_8215]  
 Daniel Hayes, M.D.  
University of Michigan  
Email: [EMAIL_8216]   
  
Mark Pegram, M.D.  
Stanford Medicine Cancer Institute 
Email: [EMAIL_8217]   
 Marc Lippman, M.D.  
University of Miami  
Email: [EMAIL_8218]  
Matthew Goetz, M.D.  
Mayo Clinic  
Email: [EMAIL_8219]  
 
Amy Krie, M.D.  
Avera Cancer Institute Email:  [EMAIL_8220]
 
 Julie Nangia, M.D.  
Baylor College of Medicine  
Email:  [EMAIL_8221]  
 Massimo Cristofanilli, M.D. 
Northwestern University  
Email:  [EMAIL_8222]
 
 
  
Version 03/16/2020 – Amendment 13   Page 5 of 87 SCHEMA – Part I  (closed)  
 
   
  
  
      
 
      
 
 
    
      
* 4-week Cycle  
† may escalate to [ADDRESS_544955] Cancer, HER2 - 
Pre-registration  
Tumor DNA Sequencing for  
HER2 Mutation  
Mutation 
Present  
 
Mutation 
Absent  
 
Study Therapy  
Neratinib 240 mg† P.O. daily  
days 1- 28 each cycle*  
Not Eligible for Study Therapy  
Restage every 2 cycles  
Continue therapy until disease progression, 
or unacceptable adverse events,  
or patient refusal  
Registration  
 
Version 03/16/2020 – Amendment 13   Page 6 of 87 SCHEMA – Part II  
 
 
 
 
 
  HER2 mutation identified in 
tumor tissue  
or circulating tumor DNA  
in a CLIA laboratory  HER2 mutation status unknown  
Central Tumor DNA sequencing 
for HER2 mutation  
Mutation Present  Mutation Absent  
Not Eligible for 
Study Therapy  
Registration  Metastatic Breast Cancer, HER2 - 
Pre-registration  
ER- ER+  
ER- Cohort  
 Fulvestrant naïve ER+ Cohort or 
Fulvestrant treated ER+ Cohort  
 
Neratinib 240mg † PO daily days 1 -28 each 
cycle∆ Neratinib 240mg † PO daily days 1 -28 each 
cycle∆ 
+  
Fulvestrant 500mg IM cycle 1 day 1 and 
day 15, then on day 1 of subsequent cycles  † may escalate to 320 mg  
∆ 4-week Cycle 
Restage every 2 cycles  
Disease progression  
If trastuzumab (or FDA approved biosimilar) coverage obtained, add:  
Trastuzumb 6mg/kg IV cycle 1 day 1, followed by 4mg/kg IV cycle 1 day 15, then 4 
mg/kg IV on days 1- 15 of su bsequent cycles  
Continue therapy  until disease progression, unacceptable adverse events, or patient refusal  
 
Version 03/16/2020 – Amendment 13   Page 7 of 87  
Glossary of Abbreviations  
 
AE Adverse event  
ALT (SGPT)  Alanine transaminase (serum glutamate pyruvic transaminase)  
ANC  Absolute neutrophil count  
AST (SGOT)  Aspartate transaminase (serum glutamic oxaloacetic transaminase)  
BUN  Blood urea nitrogen  
CBC Complete blood count  
CLIA  Clinical Laboratory Improvement Amendments  
CNS  Central nervous system  
CR Complete remission  
CRF  Case report form  
CT Computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
DLTs  Dose Limiting Toxicities  
DNA  deoxyribonucleic acid  
DSM  Data and Safety Monitoring  
DSMC  Data Safety Monitoring Committee  
EC Ethics Committee  
ECG (or EKG)  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group 
EDTA  
EGFR  
ER ethylenediaminetetraacetic acid  
Epi[INVESTIGATOR_430888]2  Good Clinical Practice  
Human epi[INVESTIGATOR_3506] 2  
HHS  Department of Health and Human Services’  
HIV Human Immunodeficiency Virus  
HRPO  
IHC Human Research Protection Office (IRB)  
Immunohistochemistry 
IND Investigational New Drug  
IRB Institutional Review Board  
ITT 
IULN  
ILLN  Intent -to-treat 
Institutional Upper Limit of Normal  
Institutional Lower Limit of Normal  
IV Intravenous (i.v.)  
LDH  Lactate dehydrogenase  
LPS lipopolysaccharide  
MedDRA  Medical Dictionary for Regulatory Activity  
MRI  Magnetic resonance imaging  
MTD Maximum tolerated dose  
 
Version 03/16/2020 – Amendment 13   Page 8 of 87 NCCN  National Cancer Center Network  
NCI National Cancer Institute  
NIH National Institutes of Health  
OHRP  Office of Human Research Protections  
ORR Overall response rate  
OS Overall survival  
PB Peripheral blood  
PBMC  Peripheral blood mononuclear cell  
PD Progressive disease 
PI [INVESTIGATOR_430889] (Partial remission)  
QASMC  Quality Assurance and Safety Monitoring Committee  
RBC Red blood cell (count)  
RECIST  Response Evaluation Criteria in Solid Tumors (Committee)  
RFS Relapse free survival  
RR Response rate  
SAE  Serious adverse event  
SCC Siteman Cancer Center  
SD Stable disease  
TF Treatment failure  
TTP Time to progression  
WBC White blood cell (count)  
WHO World Health Organization  
  
 
Version 03/16/2020 – Amendment 13   Page 9 of 87  
Table of Contents  
SCHEMA – Part I (closed)  ................................ ................................ ................................ ................................ ..................  5 
SCHEMA – Part II  ................................ ................................ ................................ ................................ ................................ . [ADDRESS_544956] Cancer  ................................ ................................ ................................ .... 11 
1.2 Neratinib ................................ ................................ ................................ ................................ ................................ . 12 
1.3 Fulvestrant  ................................ ................................ ................................ ................................ .............................  14 
1.4 Trastuzumab (Herceptin) ................................ ................................ ................................ ................................ ... 15 
1.5 HER2 (ERBB2)  ................................ ................................ ................................ ................................ ......................  17 
1.6 Mutation in HER2 (ERBB2)  ................................ ................................ ................................ ..............................  17 
1.7 Preliminary Results from Part I with Single Agent Neratinib  ................................ ................................  20 
1.8 Correlative Studies Background ................................ ................................ ................................ .....................  21 
2.0 OBJECTIVES  ................................ ................................ ................................ ................................ ...........................  21 
2.1 Primary Objectives  ................................ ................................ ................................ ................................ ..............  21 
2.2 Secondary Objectives  ................................ ................................ ................................ ................................ ..........  21 
2.3 Exploratory Objectives  ................................ ................................ ................................ ................................ ....... 22 
3.0 PATIENT SELECTION  ................................ ................................ ................................ ................................ ..........  22 
3.1 Pre-registration (for patients with unknown HER2 mutation status to have tumor tissue 
screened centrally by [CONTACT_193262] U GPS laboratory)  ................................ ................................ ................................ ....... 22 
3.2 Registration (for patients positive for HER2 mutation to receive study treatments)  .....................  23 
3.3 Inclusion of Women and Minorities  ................................ ................................ ................................ ...............  25 
4.0 REGISTRATION PROCEDURES  ................................ ................................ ................................ .......................  26 
4.1 Pre-Registration (for patients with unknown HER2 mutation status to have tumor tissue 
screened centrally by [CONTACT_193262] U GPS laborat ory) ................................ ................................ ................................ ....... 26 
4.2 Registration for Study Therapy  ................................ ................................ ................................ .......................  27 
4.3 Recruitment through Army of Women  ................................ ................................ ................................ ..........  28 
4.4 Recruitment from Outside Practice  ................................ ................................ ................................ ................  28 
5.0 TUMOR HER2 SEQUENCING  ................................ ................................ ................................ ............................  28 
5.1 Tumor HER2 sequencing at Washington University CLIA lab following pre -registration for 
eligibility  ................................ ................................ ................................ ................................ ................................ ...............  28 
5.2 Tumor or circulating tumor DNA HER2 Mutation/Variants Identified at Laboratories other 
than GPS@WU  ................................ ................................ ................................ ................................ ................................ ... 29 
5.3 Eligible HER2  mutations  ................................ ................................ ................................ ................................ ... 29 
5.4 Germline DNA Sequencing for HER2  to determine eligibility  ................................ ................................  30 
5.5 HER2 Mutation Testing by [CONTACT_412316] ................................ ................................ ................................ ..................  30 
6.0 TREATMENT PLAN  ................................ ................................ ................................ ................................ ...............  31 
6.1 Neratinib Administration  ................................ ................................ ................................ ................................ ... 31 
6.2 Concurrent Prophylactic Administration of Loperamide  ................................ ................................ ........  31 
6.3 Fulvestrant Administration  ................................ ................................ ................................ ..............................  31 
6.4 General Concomitant Medication and Supportive Care Guidelines  ................................ ....................  31 
6.5 Women of Childbearing Potential  ................................ ................................ ................................ ...................  37 
6.6 Duration of Therapy  ................................ ................................ ................................ ................................ ............  37 
6.7 Durati on of Follow -up ................................ ................................ ................................ ................................ ........  38 
7.0 DOSE DELAYS/DOSE MODIFICATIONS AND AE MANAGEMENT  ................................ .....................  [ADDRESS_544957] Compliance  ................................ ................................ ................................ ................................ ............  44 
7.7 Fulvestrant Dose Modifications  ................................ ................................ ................................ .......................  44 
7.8 Trastuzumab (or FDA Approved Biosimilar) Dose Modifications  ................................ .........................  44 
8.0 REGULATORY AND REPORTING REQUIREMENTS  ................................ ................................ ................  44 
8.1 Reporting to the Human Research Protection Office (HRPO) at Washington University  ..............  45 
8.2 Reporting to the Quality Assurance and Safety Monitoring Committee (QASMC) at Washington 
University  ................................ ................................ ................................ ................................ ................................ ............  45 
8.3 Secondary Sites Reporting Requirements  ................................ ................................ ................................ .... 45 
 
Version 03/16/2020 – Amendment 13   Page 10 of 87 8.4 Reporting to  Secondary Sites  ................................ ................................ ................................ ...........................  45 
8.5 Reporting to the FDA ................................ ................................ ................................ ................................ ..........  46 
8.6 Reporting to Puma Biotechnology, Inc.  ................................ ................................ ................................ ........  47 
8.7 Timeframe for Reporting Required Events  ................................ ................................ ................................ ... 47 
9.0 PHARMACEUTICAL INFORMATION ................................ ................................ ................................ ...............  47 
9.1 Neratinib ................................ ................................ ................................ ................................ ................................ . 47 
9.2 Fulvestrant  ................................ ................................ ................................ ................................ .............................  48 
10.0  CORRELATIVE S TUDIES  ................................ ................................ ................................ ................................ .... 50 
10.1  Required archival tumor sample for research:  ................................ ................................ ...........................  50 
10.2  Required research blood collection  ................................ ................................ ................................ ................  50 
10.3  Optional research tumor biopsy (kits will be provided):................................ ................................ ..........  50 
10.4  Reporting of a CLIA multi -gene NGS on tumor biopsy collec ted at disease progression on study 
drug:  [ADDRESS_544958] – Solid Tumors  ................................ ................................ ................................ ....................  56 
13.2  Disease Parameters  ................................ ................................ ................................ ................................ .............  56 
13.3  Methods for Evaluation of Measurable Disease  ................................ ................................ .........................  57 
13.4  Response Criteria  ................................ ................................ ................................ ................................ .................  59 
14.0  DATA AND SAFETY MONITORING  ................................ ................................ ................................ .................  61 
14.1  Independent Research Monitor  ................................ ................................ ................................ .......................  62 
15.0  AUDITING  ................................ ................................ ................................ ................................ ................................ . 63 
16.0  STATISTICAL CON SIDERATIONS  ................................ ................................ ................................ ...................  63 
16.1  Study Objectives  ................................ ................................ ................................ ................................ ..................  63 
16.2  Study Design and Sample Size Justification  ................................ ................................ ..............................  64 
16.3  Data Analysis ................................ ................................ ................................ ................................ ........................  65 
17.0  MULTICENTER REGULATORY REQUIREMENTS  ................................ ................................ .....................  66 
18.0  REFERENCES  ................................ ................................ ................................ ................................ .........................  68 
APPENDIX A: ECOG P ERFORMANCE STATUS SCALE  ................................ ................................ .......................  74 
APPENDIX B PATIENT’S MEDICATION DIARY  ................................ ................................ ................................ ...... 75 
APPENDIX C: PATIENT INSTRUCTIONS FOR THE MANAGEMENT OF DIARRHEA ...............................  76 
APPENDIX  D: RECIST 1.1 Tumor Evaluation Form  ................................ ................................ ............................  80 
APPENDIX E: Definitions  ................................ ................................ ................................ ................................ ................  81 
APPENDIX F: Reporting Timelines  ................................ ................................ ................................ .............................  84 
APPENDIX G: Serious Adverse Event Report ing Cover Sheet  ................................ ................................ ........  87 
  
 
Version 03/16/2020 – Amendment [ADDRESS_544959] Cancer 
 
Over 80% of breast cancers are HER2 negative (HER2 -), defined by [CONTACT_430923]2  gene 
amplification, for which targeted therapi[INVESTIGATOR_186621]. The prognosis for the estrogen receptor 
negative (ER -)/HER2 - subset is particularly poor [1]. Although patients with ER+/HER2-  disease 
fair better, resistance to endocrine manipulation develops almost invari ably[2]. The median 
survival is only 18- 24 months when chemotherapy is necessary in the metastatic setting[ 3]. There 
is a significant unmet clinical need to uncover new drug targets to improve the outcome of these patients.  
 
HER2/neu (ERBB2) is a well established proto -oncogene that encodes a receptor  tyrosine kinase 
of the Epi[INVESTIGATOR_14907] (EGFR) family [4]. Receptor activation via 
heterodimerization between HER2 and EGFR and other family members leads to strong mitogenic signals and cellular proliferation [5]. HER2 -targeted agents are among the most successful cancer 
therapeutics in the clinic, revolutionizing the care for patients with HER2+ breast cancer [6-11]. 
HER2+ breast cancer is defined clinically by [CONTACT_430924]2 protein overexpression on 
immunohistochemistry (IHC) or HER2 gene amplification by [CONTACT_187044] 
(FISH) testing  and occurs in approximately 15- 20% of all breast  cancer cases. HER2 - breast 
cancers as a whole have not been shown to derive benefit from these highly effective agents[ 12].  
 Results from The Cancer Genome Atlas (TCGA) breast cancer project demonstrated that a small 
subpopulation of HER2 - breast cancer carry mutations in HER2, with majority being in the kinase 
domain and compi[INVESTIGATOR_430890] 1,[ADDRESS_544960] cancers documented 22 cases of somatic HER2 
mutation, a mutation rate of 1.6% [13-15].  In addition, laboratory investigations indicated that 
many of t hese mutations  are activating mutations , with the capacity to induce cellular 
transformation and importantly an enhanced susceptibility to the inhibitory effects of anti -HER2 
agents  (see Preliminary Investigation section). These discoveries raised the possibility that 
mutations in HER2 could be effectively targeted by [CONTACT_430925] -HER2 agents in the 
clinic. The objective of this application is to establish HER2 mutation as a therapeutic target in HER2 - breast cancer. We therefore propose a phase II study of neratinib, a pan HER inhibitor, in 
metastatic HER2 -/HER2 mutated breast cancers for tumor response.   
 As of January 17, 2015, the study enrolled 11 patients with HER2 mutations, among which 10 
patients had ER+ breast cancer.  Considering the well-established signaling crosstalk between ER 
and HER2 in ER+ HER2+ breast cancer
16,17, we propose to add the ER down regulator fulvestrant 
to neratinib  in the ER+ subpopulation in the second part of this trial.  
 
Although the prevalence of HER2 mutation is low, because breast cancer is so common this would 
account for approximately 4,000 new cases each year in the US alone, an annual incidence that is very similar to chronic myeloid leukemia (CML), a disease transformed by [CONTACT_430926].  
  
 
Version 03/16/2020 – Amendment 13   Page 12 of 87  
1.2 Neratinib  
 
1.2.1 Mechanism of Action  
 
Neratinib (PB -272) is a potent irreversible pan HERB inhibitor.  Neratinib is an oral ly 
available small molecule that inhibits HER- 1, HER- 2, and HER- 4 at the intracellular 
tyrosine kinase domains, a mechanism of action that is different from trastuzumab [16-18].  
Neratinib reduces HER- [ADDRESS_544961] antitumor activity  in HER- 1 - and/or HER- 2-expressing carcinoma cell lines, with 
cellular IC50 <[ADDRESS_544962] the 2 kinases in vitro.  
 
1.2.3 Neratinib Phase 1 and Pharmacokinetic Data  
 
Preliminary  pharmacokinetic ana lyses demonstrated that neratinib absorption was 
relative ly slow, and the maximum conc entration (C
max) was general ly attained within 3 to 
6 hours.  After oral administration, the neratinib C max and area under the conce ntration 
versus time curve (AUC) increased in a dose -dependent manner in general.  Mean stead y-
state Cmax and AUC values were 70.1 ng/mL and 975 ng·h/mL  for the 180 -mg dose group, 
respectivel y, 73.5 ng/mL and 939 ng ·h/mL  for the 240 -mg dose group, respectivel y, 90.4 
ng/mL and 1333 ng ·h/mL  for the 320- mg dose group, respective ly, and 105 ng/mL and 
1704 ng ·h/mL  for the highest dose  of 400 mg, respective ly.  The neratinib exposure (AUC) 
increased 1.2 - to 2.7- fold (mean accumulation ratio) when comparing the stea dy-state 
exposure on day 21 after repeated daily administration with the exposure on day 1 after 
administration of 80 to 400 mg of neratinib.  The mean accumulation ratio was 1.2 after a 240-mg dose, indicating no significant accumulation of neratinib after repeated daily  dose 
administration at the dose to be used in this proposed trial. The data indicated a slow distribution of neratinib with a large apparent volume of distribution (Vz/F on day 1: about 
3188 to 6181 L) after oral absorption.  After oral administration on day  1, neratinib was 
eliminated with a mean apparent terminal half -life (t ½) of approximately 13 to 17 hours.  
There was moderate to large variability in neratinib t ½, C
max, and AUC; coefficients of  
variation general ly ranged from 8% to 90%. In the single agent, first in human, phase 1 
study 3144A1- 102-US, neratinib single agent administered orall y was given in increasing 
 
Version 03/16/2020 – Amendment 13   Page 13 of 87 doses from 40 mg to 400 mg.  Diarrhea was the main dose limiting toxicity (DLT) observed.  
At the 400 -mg dose level, 4 of 6 subjects had DLT of grade 3 diarrhea.  Thus, the maximum 
tolerated dose (MTD) was determined to be 320 mg per da y.  However, due to the frequency 
and severity  of neratinib -related diarrhea observed in subseque nt subjects treated at the 
MTD (34% of subjects reported grade 3 diarrhea), the MTD was reevaluated to [ADDRESS_544963] cancer [ 19].   In this trial, patients will receive [ADDRESS_544964] 3 patients treated in this trial, we elected to allow dose escalation to 320mg in subsequent cycles, with initial prophylactic use of lopera mide, in patients who tolerated the 240mg daily dosing.  
 
1.2.4 Singl e-Agent Activity of Neratinib in HER2+ Breast Cancer 
 
Neratinib as a single agent has been studied in a phase [ADDRESS_544965] cancer  [19].  Sixty-six (66) subjects with prior trastuzumab based 
therapy were enrolled into arm A; 70 subjects without any prior trastuzumab exposure were 
enrolled into arm B.  Objective response rate and median progression free survival were 
used as estimates of  antitumor activity . For patients with prior trastuzumab treatment, the 
objective response r ate was 24% (95% CI, 14% to 36%); for patients with no prior 
trastuzumab treatment, the objective response rate was 56% (95% CI, 43% to 69%). Six 
and eight patients with and without prior trastuzumab treatment, respectively, had stable 
disease for at least  24 weeks that yielded clinical benefit rates of 33% and 69%. The median 
duration of objective tumor response was 39.3 weeks (95% CI, 32.3 weeks to 93.7 weeks) 
for patients with prior trastuzumab treatment and 52.4 weeks (95% CI, 33.1 weeks to not estimabl e) for patients with no prior trastuzumab treatment. The median onset of first 
complete response or partial response was rapid at 7.1 weeks for patients both with and 
without prior trastuzumab treatment (prior trastuzumab range, 3.0 to 24.0 weeks; no prior  
trastuzumab range, 3.1 to 15.6 weeks; 75th percentile, 7.1 weeks for both). Similar efficacy 
results were obtained by [CONTACT_3138].  
 
1.2.[ADDRESS_544966] cancer study, diar rhea was the only grades 3 
to 4 adverse event that occurred in more than 10% of patients (28 patients with grade 3; one 
patient with grade 4) and was the predominant adverse event associated with dose reductions, which were required in 29% of patients with prior trastuzumab treatment and in 
4% of patients with no prior trastuzumab treatment. However, only one patient (with prior trastuzumab treatment) discontinued treatment because of grade 2 diarrhea. The onset of diarrhea occurred early in the course of t herapy (median time to onset, 2 to 3 days) and 
lasted a median of 5 to 7 days per event. Diarrhea severity abated during multiple weeks of treatment. During study week 1, diarrhea occurred in 70% to 90% of patients and decreased to 10% to 15% of patients a fter month 2. Only one patient had grade 3 diarrhea after month 
2. With use of antidiarrheals and dose modification, neratinib treatment was continued in 99% of patients, despi[INVESTIGATOR_430891]. Mild, often transient, ski n rashes were observed in approximately one quarter of the patients.  
 Other common AEs are nausea, vomiting, fatigue, anorexia, abdominal pain, asthenia, 
dehydration, rash, elevated alanine aminotransferase (ALT), and e levated aspartate 
 
Version 03/16/2020 – Amendment 13   Page 14 of 87 aminotransferase ( AST).  The above AEs are considered to be adverse drug reactions fo r 
neratinib.  
 
As opposed to treatment with other HER -2 targeted agents, such as trastuzumab, 
cardiotoxicity  has not been observed with neratinib, even in subjects previously treated with 
anthrac yclines and/or trastuzumab.  
 Interstitial lung disease, which can sometimes be fatal, has been reported with other oral tyrosine kinase inhibitors that target EGFR (HER -1) +/ - HER2 (HER- 2), including 
lapatinib, gefitinib,  and erlotinib.   Pneumonitis which was considered to be drug related, 
according to the investigator’s assessment, has been reported in clinical studies of neratinib.  Subjects receiving neratinib should be monitored for acute onset or worsening of  pulmonary  
symptoms such  as dyspnea, cough, and fever and treated appropriatel y. There has been one 
event of bone marrow suppression reported on December 9, 2009, in a subject who was taking neratinib monothera py for [ADDRESS_544967] recent version of the investigator’s 
brochure for a summary of findings from nonclinical studies that potentially have clinical 
significance and from clinical studies that are relevant to the stu dy.  Also, refer to the most 
recent version of the inv estigator’s brochure for a summary of the known and potential risks 
and benefits to human subjects.  
 
1.3 Fulvestrant  
 
1.3.1 Fulvestrant in the Treatment of ER+ Breast Cancer 
 
Fulvestrant (Faslodex) is an estrogen receptor a ntagonist  that binds to ER and leads to its 
degradation, a distinct mechanism of action from other endocrine therapy agents that  target 
ER. Fulvestrant blocks ER action without agonist effect . It is FDA approved for  patients 
who have disease progression  on other antiestrogen agents in the advanced breast cancer 
setting.  In two phase III trials, fulvestrant [ADDRESS_544968] to disease progression and overall survival  [20, 21]. In 
the EFECT trial, fulvestrant [ADDRESS_544969] as effective as 
exemestane in patients with metastatic ER+ breast cancer  resistant to non -steroidal AIs  [22]. 
In the CONFIRM trial, high- dose fulvestrant at 500 mg monthly was found to be more 
effective compared to the previous  dosing of 250 mg monthly, which prompted FDA’s 
subsequent  approval of fulvestrant [ADDRESS_544970] 
cancer [23].  
 
Overall, fulvestrant demonstrated an over all response rate of approximately 10% in 
aromatase inhibitor resistant, fulvestrant naive ER+ HER2 - breast cancers [ 24, 25].  There 
is no data at this time regarding the activity of fulvestrant in ER+ HER2 - breast cancer with 
HER2 mu tations.  However its efficacy in ER+ HER2+ breast cancer has been described in 
a retrospective study [ 26].  In this study, fulvestrant resulted in an overall response rate of 
9% and clinical benefit rate of 42% (43/101 patients), with anti -tumor activity observed in 
up to the fourth line of endocrine therapy and seventh line of overall therapy [ 26].  Since 
the response rate approxi mated 10% in both HER2+ and HER2-  population based on the 
studies described above, we assume  a similar response rate of 10% in fulvestrant naïve 
HER2 mu tant patient population in this trial.    
 
 
Version 03/16/2020 – Amendment 13   Page 15 of 87 1.3.2 Fulvestrant in Combination with Receptor Tyrosine Kinase Inhi bitor the 
Treatment of ER+ Breast Cancer  
 
Although there is no data in the literature for the combination of fulvestrant and neratinib in ER+ breast cancer, fulvestrant was combined with the HER1/HER2 inhibitor lapatinib in a randomized phase III trial of fulvestrant with or without lapatinib in patients with AI resistant metastatic ER+ HER2 1+, 2+, 3+ [ 25].  The  study demonstrated an overall 
response rate of 9% in the fulvestrant plus placebo arm and 20% in the fulvestrant plus lapatinib arm, with anticipated side effects observed with single agents alone [ 25].   
 Since fulvestrant is well tolerated, there is no obvious theoretical pharmacokinetic interaction between neratinib and fulvestrant , and the mechanism of action of neratinib is 
similar to lapatinib, we do not anticipate th e side effects profile be different from single 
agent therapy with neratinib and fulvestrant.    
 
1.3.[ADDRESS_544971] common adverse reactions reported in the fulvestrant study groups, regardless of 
causality, were GI symptoms i ncluding nausea and vomiting (26%/13%), constipation 
(12.5%), diarrhea (12.3%) and abdominal pain (11.8%); as well as headache (18.9%); back pain (15.4%); hot flashes (17.7%); and pharyngitis (16.1%). Vaginal bleeding was reported 
in < 1% of patients and occurred most commonly during the first 6 weeks after changing 
from existing hormonal treatment to fulvestrant. If vaginal bleeding persists, further 
evaluation is required. Injection site reaction with mild transient pain (9.1 -11.6%) and 
inflammation were seen with fulvestrant. Seven percent of patients (1% of treatments) given 
a single 5 ml IM injection and 27% of patients (4.6% of treatments) given 2 x 2.5 ml IM injections experienced reactions. Additional adverse reactions occurring in > 5% of patients treated with fulvestrant during clinical trials include asthenia (weakness) (68.3%), bone 
pain (15.8%), dyspnea (14.9%), increased cough (10.4%), pelvic pain (10%), anorexia 
(9%), peripheral edema (9%), rash (unspecified) (7.3%), chest pain (unspecified) (7 .1%), 
dizziness (6.9%), insomnia (6.9%), fever (6.4%), paresthesias (6.4%), urinary tract 
infection (6.1%), depression (5.7%), anxiety (5%), diaphoresis (5%), and anemia (4.5%).  
 Other adverse events reported as fulvestrant -related and occurring infrequent ly (< 1%) 
include thromboembolism, myalgia, vertigo, and leukopenia. In addition, hypersensitivity 
reactions such as angioedema and urticaria have been infrequently reported.  
 
1.4 Trastuzumab (Herceptin)  
 
1.4.1 Mechanisms of Action  
 
Trastuzumab is an IgG1 kappa that  selectively binds to the extracellular domain of the 
HER2 receptor.  Trastuzumab inhibits HER2+ breast cancer cell proliferation in preclinical 
models [27, 28].  In addition, trastuzumab is a mediator of antibody -dependent cellular 
cytotoxicity (ADCC)[ 29, 30] . 
 
1.4.[ADDRESS_544972] cancer [ 31].  In a study of single agent 
 
Version 03/16/2020 – Amendment 13   Page 16 of 87 trastuzumab, administered 4mg/kg loading dose followed by 2mg/kg weekly, or 8mg/kg 
loading dose and 4mg/kg weekly, as first -line therapy for HER2 -overexpressing breast 
cancer, the objective response rate was 35%  in HER2 3+ and 34% in HER2 amplified cases[ 32]. In another phase II trial of single agent trastuzumab in HER2+ breast cancer, 
trastuzumab was administered 8 mg/kg then 6 mg/kg Q3 weeks and the clinical benefit rate was 33% [33]. In patients who had received extensive prior therapi[INVESTIGATOR_014], the objective response 
rate was found to be around 15% [ 34].  Trastuzumab also demonstrated its ability to reduce 
cancer recurrence and death in the adjuvant setting as demonstrated by [CONTACT_430927] -
center randomized controlled trials [ 8, 35]. Trastuzumab is a recombinant DNA -derived 
humanized monoclonal antibody against HER2 and is approved by [CONTACT_430928]2.  
 
1.4.3 Dual Targeting in HER2+ Breast Cancer  
 
Approximately 15% of HER2+ breast cancer patients relapse after initial therapy with trastuzumab. [36] Preclinical evidence has shown synergistic interaction between 
trastuzumab and other HER -[ADDRESS_544973] shown that 
dual HER2 targeting may prolong time to resis tance and improve survival outcomes.[ 37] A 
double -blind phase III study (CLEOPATRA) compared first -line trastuzumab plus 
pertuzumab plus docetaxel with trastuzumab plus placebo plus docetaxel in 808 patients with metastatic HER2+ breast cancer. T he pertuzumab arm had longer median progression 
free survival (PFS) (19 months vs. 12 months; HR=0.62; 95% CI, 0.51- 0.75; P <0.001) and 
overall survival (OS) (not yet reached in pertuzumab arm vs. 37.6 months; HR 0.66; 95% 
CI, 0.52- 0.84). [38] A randomized phase III, study of single agent lapatinib vs. combination 
of trastuzumab plus lapatinib in patients with HER2+ metastatic breast cancer who had 
disease progression on prior trastuzumab -based therapy  showed superior PFS (HR=0.73; 
95% CI, 0.57- 0.93; P =0.008) and clinical benefit rate (CBR)  (24.7% in the combination 
arm vs. 12.4%  in the monotherapy arm ; P =0.01) for the combination arm . There was also 
a median OS advantage seen in the combination arm (14 months vs 9.5 months; HR 0.74; 95% CI 0.75- 0.97; P=0.026). The side effect profile is favorable with the combination arm 
showing a higher incidence of diarrhea ( P=0.03). [39] A meta -analysis examining the 
cardiac toxicity in breast cancer patients treated with dual HER2 blockade showed no 
significant increase in cardiotoxic ity, although the trials generally only inc luded patients 
with good baseline cardiac function and patients who have tolerated prior treatment with 
trastuzumab,[ 40] Long term outcomes on cardiac toxicity remain to be seen. 
 
1.4.4 Neratinib in Combination with Trastuzumab  
 
A phase I/II, nonrandomized, open label study of neratinib in combination with trastuzu mab 
was performed in women with advanced HER2+ breast cancer. [41] The phase I, dose -
escalation phase enrolled 8 patients. No DLT was reported and the recommended dose of 
neratinib was 240mg daily in combination with trastuzumab 4mg/kg loading dose followed by 2mg/kg weekly thereafter. In phase II, 37 patients received neratinib and trastuzumab at the recommended dose and 28 patients were evaluable for efficacy. In the evaluable population, the 16- week PFS rate was 44.8% (95% CI, 25.9 –  62.1%), and the median PFS 
was 15.9 weeks (95% CI 15.1 – 31.3), with data censored for  [ADDRESS_544974] overall response of complete response (CR), 6 patients had partial response (PR) and 14 patients had stable disease (SD). The overall response rate was 28.6% (95% CI, 13.2 – 48.7%) and the clinical benefit rate (CBR) was 35.7% (95% CI, 18.6 – 55.9%).[ 41]   
 
 
Version 03/16/2020 – Amendment 13   Page 17 of 87 In this trial, trastuzumab  (or FDA approved biosimilar)  will be added to the study drug 
neratinib or neratinib and fulvestrant (ER+ cohort, Part II of the trial) at disease progressi on 
if insurance coverage is obtained  to explore the activity of combined HER2 targeting in 
HER2 mutant breast cancer.  
 
1.5 HER2 (ERBB2)  
 
HER2/neu (ERBB2), located on chromosomal 17q21.1, is a  well established proto -oncogene that 
encodes HER2, a transmembrane  tyrosine kinase receptor  of the EGF receptor (EGFR) family  
composed of  four members (EGFR/HER1, HER2, HER3 and HER4) that contain an extracellular 
ligand -binding domain, a lipophilic transmembrane domain, and an intracellular tyrosine kinase 
domain [4]. Receptor activation via heterodimerization between HER2 and EGFR and other 
members leads to strong mitogenic signals and cellular proliferation[ 5].  
 
The identification of HER2 gene amplification and the subsequent invent of HER2- targeted agents 
have revolutionized the care of patients with breast cancer [ 11].  Approximately 20% of invasive 
breast  cancer cases carry HER2  gene amplification, leading to increased HER2 protein expression, 
an aggressive clinical behavior and a decreased disease free and overall survival  [42-44].  
Trastuzumab, a monoclonal antibody against HER2, was the first anti -HER2 agent which was 
found to markedly improve the survival of patients with HER2 positive breast cancer in both metastatic and early stage setting [ 6-10], establishing one of the first molecular cancer therapi[INVESTIGATOR_014].  
Multiple agents are currently available in clinical practice either approved by [CONTACT_430929]2 positive breast cancer defined by [CONTACT_430924]2 overexpression 
or gene amplification [ 11].  
 
1.6 Mutation in HER2 (ERBB2)  
 
1.6.[ADDRESS_544975] cancer sequencing projects [15, 45-49] 
and identified 15 HER2 somatic mutations in 22 out of the 1391 
patients, an overall incidence of 1.6% (Fig. 1).  Mild enrichment for HER2 mutation s may 
occur in lobular breast cancer as three HER2 somatic mutations were observed in [ADDRESS_544976] cases in the TCGA study [50] and three were observed among 113 lobular cases in 
Shah et al., suggesting a prevalence of 4% in this histological subtype [46]. Mutations 
clustered in two locations, the extracellular domai n (ECD) at aa 309- 310 ( 5 of 25) and the 
kinase domain between aa 755- 781 (17 of 25).  
 
  
Fig. 1.  HER2 som atic mutations from 22 patients  
 
Blue circles represent individual cases.  
 
Version 03/16/2020 – Amendment 13   Page 18 of 87 1.6.2 Preclinical Functional Characterization of HER2 Mutations [51] 
 
Effects on kinase activities : We successfully expressed HER2 kinase dom ain constructs 
for WT, and V777L, D769H, V842I mutants and purified them to >80% purity. In vitro 
kinase assays demonstrated that both the D769H -HER2 and the V777L -HER2 had greater 
tyrosine kinase activity than WT -HER2 (Figure 2, left) and were sensitive t o lapatinib in 
vitro (Figure 2, right). In contrast, V842I -HER2 showed modestly increased kinase activity 
and a small shift in lapatinib in vitro  IC50 (22 vs 10 nM).   
 
 
Effects  on Signaling and Growth:  HER2 mutations were introduced into non-
transformed, MCF10A breast epi[INVESTIGATOR_430892] a 
retroviral vector.  The V777L, D769H, D769Y, P780ins, V842I , and R896C  mutants are activating 
mutations that increased HER2 autophosphoryl ation 
and substrate protein (phospholipase γ C1, PLCγ) phosphorylation relative to WT HER2 (Fig. 3).  Modest increases in HER2, PLCγ, and EGFR phosphorylation were seen with G309A, L755S, and R678Q.  HER2 del.755- [ADDRESS_544977] Cγ phosphorylation, but 
increased EGFR phosphorylation, which suggests that del.755 -759 has an increased ability to activate 
other HER/ErbB family members.  The ability of various TKI drugs to block signaling from HER2 
mutations was tested (not shown) and we observed that L755S mutation is a lapatinib- resistant mutation 
that is sensitive to neratinib and canertinib.  While all three drugs are HER2/EGFR selective, lapatinib is a reversible inhibitor[ 52].  In contrast, neratinib and 
canertinib are irreversible inhibitors that form a covalent bond with a Cys residue in HER2’s active site[ 53]. WT D769H V777L V842ISpecific Activity
(pmol product/ µg Her2/min)
050100150200250
Monomer
Dimer
2.3-fold5-fold22-fold33-fold
20-fold
3.3-fold7.5-fold
A 
Lapatinib (nM)0.01 0.1 1 10 100Relative activity (%)
020406080100WT
D769H
V777L
V842I
     HER2     IC50(nM)
      WT           10
    V777L          8
    D769H       10
     V842I        22
B 
Fig. 2.  In vitro  kinase activity of HER2 mutations  
(A) fold change values are relative to HER2 monomers.  
(B) In vitro inhibition by [CONTACT_430930].  
Fig. 3.  Activation of downstream 
signaling by [CONTACT_94970]2 mutations.   
KD indicates kinase domain 
mutations; JM:  juxtamembrane; 
ECD:  extra -cellular domain.  

 
Version 03/16/2020 – Amendment [ADDRESS_544978] on cell growth and morphology in three dimensional cultures was measured. As previously reported [54, 55], 
MCF10A -HER2 WT formed 
spherical structures (Fig. 4, upper left).  MCF10A cells bearing HER2 V777L, D769H, D769Y, P780ins, V842I, R896C, or 
G309A mutations formed 
irregular structures with spi[INVESTIGATOR_430893], invading protrusions (Fig. 4, top row).   Addition of the HER2 antibody, trastuzumab, restored the spherical morphology to these mutations (Fig. 4, middle row).  HER2 L755S, del.755- 759, and R678Q formed spherical structures, similar 
to WT HER2.  MCF10A cells are an EGF -dependent cell line and require supplementary 
EGF in their media.  Addition of lapatinib, a dual HER2/EGFR inhibitor, blocked the growth of MCF10A -HER2 WT cells and most of the HER2 mutant cells (Fig. 4, lower 
row).  Interestingly, L755S and del.755- 759 were resistant to  this dose of lapatinib and 
continued to form large spherical structures, but they were sensitive to the irreversible inhibitor, neratinib (Fig. 5).  The del.755- 759 mutation was sensitive to gefitinib (Fig. 5), 
consistent with the increased activation of EGFR observed in HER2 del.755- 759 mutant 
cells (Fig. 3).   The ability of the HER2 mutations to 
increase tumor formation in xenografts was 
also tested (Fig. 6). NIH3T3- HER2 WT cells 
served as the control cell line.  NIH3T3 -
HER2 V777L, D769H, and G309A mut ant 
cell lines had more rapid tumor growth than 
the HER2 WT control (p- values all <0.01, as 
indicated in the figure by **).  The L755S, V842I, R678Q and mutations showed tumor growth indistinguishable from the HER2 WT control (Fig. 6).  These mutations did have 
more rapid tumor growth than empty vector cells, suggesting that these mutations do not impair HER2 functioning.  Xenograft experiments using MCF7 cell lines are in progress (not shown).  
 

 
Version 03/16/2020 – Amendment 13   Page 20 of 87  
 
  
Summary of HER2 preclinical  data:   To date, we have tested thirteen  HER2 somatic 
mutations , of which seven are found to be activating mutations that are sensitive to HER2 
targeted drugs: G309A, D769H, D769Y, V777L, P780ins, V842I and R896C [51]. In 
addition, a recent HER2 functional study by [CONTACT_430931]. also identified G309E and S310F as activating mutations [56]. Notably, the L755S mutation showed a lapatinib-
resistant phenotype, but was sensitive to neratinib[ 51].    
 
We hypothesize that tumors with mutations in HER2 can be effectively treated with 
neratinib. As a pi[INVESTIGATOR_799], we will conduct a 2- stage phase II single arm trial of neratinib 
in patients with HER2 -/HER2 mutation+ metastatic breast cancer.  Neratinib is ch osen as 
it is an irreversible inhibitor of HER1, HER2 and HER4 rather than lapatinib which is a reversible inhibitor of HER1 and HER2.  Importantly, neratinib has shown activity in lapatinib resistant HER2 mutations in our preclinical studies (Figure 5).   
 HER2 mutation is present in 1.6% of primary breast cancer overall, but certain subpopulation of breast cancer may have higher incidence.  We therefore plan to analyze the clinical and pathological features of tumors with or without HER2 mutation during this 
trial and preferentially screen those that are most likely to carry the HER2 mutations.  
 
1.[ADDRESS_544979] cancer carrying HER2 
mutations (Table 1).  Fifteen of these patients (94%) had ER+ disease.  Among the first 10 patients with somatic Her2 mutations (9 with activating mutations and 1 with unknown significance), 1 patient with known activating mutation HER2 L755S had a partial response to neratinib.  The study 
passed the efficacy criteria to continue enrollment to the 2
nd stage (refer to statistical section).  
Because of  the high incidence of ER positivity  in HER2 mutated breast cancer  and the well 
established  crosstalk between ER an d HER2 pathways , we propose to examine the combination of 
neratinib and fulvestrant in patients with ER+, HER2- /HER2 mutated breast cancers in Part II of 
the trial.   
Figure 6. HER2 induces growth of tumors in nude mice.   
[ADDRESS_544980] were injected subcutaneously.  
 
Version 03/16/2020 – Amendment [ADDRESS_544981] cancer prognosis and treatment response.  
   
2.0 OBJECTIVES  
 
2.1 Primary Objectives  
 
1. Part I: To determine the clinical benefit  (CR+PR+SD> 6 months) of neratinib  alone in patients 
with metastatic HER2 - breast cancer that carry HER2 mutations . 
2. Part II fulvestrant- naïve ER+ cohort : To examine the clinical benefit  (CR+PR+SD >6 months ) 
of neratinib in combination with fulvestrant in patients with fulvestrant -naïve metastatic HER2 -
, ER+ breast cancer carrying activating HER2 mutations.  
3. Part II fulvestrant- treated ER+ cohort : To examine the clinical benefit (CR+PR+SD≥6 months) 
of neratin ib in combination with fulvestrant in patients with  metastatic HER2 -, ER+ breast 
cancer carrying activating HER2 mutations previously treated with fulvestrant.  
4. Part II ER - cohort : To determine the clinical benefit rate of neratinib alone in patients with 
metastatic HER2 -, ER- breast cancer carrying activating HER2 mutations.  
 
2.[ADDRESS_544982] cancer by [CONTACT_430932]2 mutations (activating vs. unknown 
significance).  Table 1: Pathologic Characteristics of 
HER2 Mutant Breast Cancer Identified in 
Part I  (N=16)  
 
Histology  N % 
Ductal  9 56% 
Lobular  6 38% 
Unknown 1 6% 
Biomarkers    
ER +, PR +  7 44% 
ER+, PR - 8 50% 
ER-, PR - 1 6% 
 
 
Version 03/16/2020 – Amendment 13   Page 22 of 87 2. To assess the PFS and response rate  of neratinib in combination with fulvestrant in patients 
with fulvestrant- naïve metastatic ER+ HER2 - breast cancer carrying activating HER2 
mutations.  
3. To assess the PFS and response rate of neratinib in combination with fulvestrant in patients 
with metastatic ER+ HER2 - breast cancer carrying activating HER2 mutations previously 
treated with fulvestrant.  
4. To assess the safety profile and tolerability of neratinib in combination with fulvestrant in patients with metastatic ER+ HER2 - breast cancer carrying activating HER2 mutations.  
5. To correlate the presence of HER2 mutation with histology subtype (invasive lobular vs. invasive ductal cancer), tumor grade (grade 1- 2 vs 3), tumor staging at initial diagnosis (I vs. II 
or III vs. IV), disease free survival in HER2 - breast cancer .  
 
2.[ADDRESS_544983] cancer  
4. To explore potential mechanisms of treatment r esistance  
5. To explore anti -tumor response after adding trastuzumab  (or FDA approved biosimilar)  to 
neratinib or neratinib plus fulvestrant when tumor progress es on single agent neratinib or 
neratinib in combination with fulvestrant.  
 
 
3.0 PATIENT SELE CTION 
 
3.1 Pre-registration  (for patients with unknown HER2 mutation  status to have tumor 
tissue screened  centrally  by [CONTACT_193262] U GPS laboratory)  
 
3.1.1 Inclusion Criteria  for Pre- registration   
 
1. Histologically or cytological ly confirmed HER2 -negative (0 or 1+ by [CONTACT_389508]-
amplified by [CONTACT_4656])  breast cancer  that is stage IV .   
2. Agree to provide archival tumor material for research  
3. There is no limitation on the number of prior lines of systemic therapy.  
4. Presence of  measurable or non-measurable disease by [CONTACT_393]  1.1 is accep table, except 
to be eligible for the Part II fulvestrant- naïve ER+ cohort, at least one measurable 
disease by [CONTACT_393] 1.[ADDRESS_544984]  18 years  of age . 
6. ECOG performance status <  2 (see Appendix A ). 
7. Adequate  organ function as defined below  within 8 weeks of pre -registration : 
• Serum creatinin e: ≤1.[ADDRESS_544985]  
• Child -Pugh class A if with liver disease  
8. Able to understand and willing  to sign a n IRB approved  written informed consent 
document.  
 
Note : HER2 mutation testing may be performed while the patient is receiving active 
systemic therapy for metastatic breast cancer so that the result can  be used to determine 
eligibility for study drug therapy in the future.  
 
3.1.2 Exclusion Criteria  for Pre -registration  
 
Version 03/16/2020 – Amendment [ADDRESS_544986] a recent 
LVEF < LLN or have symptoms of congestive heart failure . 
2. Uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection , unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social 
situations that would limit compliance with study requirements.  
3. Acute or currently active hepatic or biliary disease requiring antiviral therapy (with the 
exception of Gilbert’s syndrome, asymptomatic gallstones, liver metastases, o r stable 
chronic liver disease per investigator assessment).  
4. History of significant cardiac disease, cardiac risk factors, or uncontrolled arrhythmias.  
5. Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs 
resulting in dyspnea at r est. 
 
3.2 Registration  (for patients positive for HER2 mutation to receive study treatments)  
 
3.2.1 Inclusion Criteria  for Registration ( for patients initially pre -registered  and 
with HER2 mutation identified by [CONTACT_193262] U GPS laboratory ) 
 
1. Tumor tissue tested positive for HER2 mutation.  Se e the list of mutations eligible for 
Part II enrollment in Table 2 (Section 5.1.6).  Mutations outside the list will be assessed 
on a case -by-case basis by [CONTACT_430933].  
Note: HER2 mutations listed in Table 2 detected by [CONTACT_86052]360 are also eligible  
2. Agree to provide archival tumor material for research  
3. ECOG performance status <  2 (see Appendix A ). 
4. Adequate organ function as defined below  within 2 weeks of registration:  
• Absolute  neutrophil  count: ≥1.5 × 109/L (1500/m m3) 
• Platelet count: ≥100 × 109/L (100,000/mm3) 
• Serum creatinin e: ≤1.[ADDRESS_544987]  
• Child -Pugh class A if with liver disease  
5. The p atient must have completed radiation therapy and be at least [ADDRESS_544988] received radiation and be off steroids and stable  (without evidence of disease progression by 
[CONTACT_430934])  for 3 months. 
8. QTc interval ≤ 450 m sec for men or ≤ 470 msec for women within 2 weeks of 
registration . 
9. LVEF >  institutional LLN  within [ADDRESS_544989] agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation.  Should a woman become pregnant or suspect she is pregnant while p articipating in this study, she must inform her treating physician 
immediately .  Men must agree and commit to use a barrier method of contraception 
while on treatment and for [ADDRESS_544990]  
(see Section 6.3) . 
11. Able to understand and willing to sign an IRB approved written informed consent 
document.  
12. There is no limitation on the number of prior lines of systemic therapy.  
 
Version 03/16/2020 – Amendment 13   Page 24 of 87 13. To be eligible for the Part II fulvestrant- naïve ER+ cohort, prior treatment with 
fulvestrant i s not allowed. In addition, ER and/or PR positivity by [CONTACT_430935] (for example, pleural effusion or ascites or bone biopsy) may yield 
false negative ER and/or PR result, in which case the pathology from an earlier time 
point could be used and a discussion with the study chair is required.  
14. To be eligible for the Part II fulvestrant- treated ER+ cohort, prior disease progression 
on fulvestrant i s required.  In addition, ER and/or PR positivity by [CONTACT_430936] (for example, pleural effusion or ascites or bone biopsy) may yield false negative ER and/or P R result, in which case the pathology from an earlier time point 
could be used and a discussion with the study chair is required. 
 
3.2.2 Inclusion Criteria  for Registration ( for patients with  HER2 mutation 
identified at an outside CLIA certified location) 
 
1. Histologically or cytological ly confirmed HER2 -negative (0 or 1+ by [CONTACT_389508]-
amplified by [CONTACT_4656])  breast cancer  that is stage IV .   
2. Tumor tissue  or circulating tumor DNA  tested positive for HER2 mutation.  See the list 
of mutations eligible for Part II enro llment in Table 2 (Section 5.1.6).  Mutations outside 
the list will be assessed on a case- by-case basis by [CONTACT_430937].  
3. Presence of  measurable or non- measurable disease by [CONTACT_393] 1.1 is acceptable, except 
to be eligible for the Part II fulvestrant- naïve ER+ cohort, at least one measurable 
disease by [CONTACT_393] 1.[ADDRESS_544991]  18 years of age.  
5. ECOG performance status <  2 (see Appendix A ). 
6. Adequate organ function as defined below  within 2 weeks of registration:  
• Absolute  neutr ophil  count: ≥1.5 × 109/L (1500/m m3) 
• Platelet count: ≥100 × 109/L (100,000/mm3) 
• Serum creatinin e: ≤1.[ADDRESS_544992]  
• Child -Pugh class A if with liver disease  
7. The p atient must have completed radiation therapy and be at least [ADDRESS_544993] received radiation and be off steroids and stable  (without evidence of disease progression by 
[CONTACT_430934])  for 3 months. 
10. QTc interval ≤ 450 m sec for men or ≤ 470 msec for women within 2 weeks of 
registration . 
11. LVEF >  institutional LLN  within [ADDRESS_544994] agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation.  Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician 
immediately .  Men must agree and commit to use a barrier method of contraception 
while on treatment and for [ADDRESS_544995] 
(see Section 6.3). 
 
Version 03/16/2020 – Amendment 13   Page 25 of 87 13. Able to understand and willing to sign an IRB approved written informed consent 
document.  
14. There is no limitation on the number of prior lines of systemic therapy.  
15. To be eligible for the Part II fulvestrant- naïve ER+ cohort, prior treatment with 
fulvestrant is not allowed. In addition, ER and/or PR positivity by [CONTACT_430938] (for example, pleural ef fusion or ascites or bone biopsy) may yield 
false negative ER and/or PR result, in which case the pathology from an earlier time point could be used and a discussion with the study chair is required.  
16. To be eligible for the Part II fulvestrant- treated ER+ cohort, prior disease progression 
on fulvestrant is required.  In addition, ER and/or PR positivity by [CONTACT_430939] (for example, pleural effusion or ascites or bone biopsy) may yield false negative ER and/or PR result, in which case the pathology from an earlier time point could be used and a discussion with the study chair is required. 
 
3.2.3 Exclusion Criteria  for Registration  
 
1. Currently receiving any other investiga tional agents  or systemic cancer therapy . 
2. Currently taking medications and herbal or dietary supplements that are  strong 
cytochrome P450 (CYP) 3A4 inducers or inhibitors (refer to Section 6. 4.4).  A washout 
period of at least [ADDRESS_544996] been completed  prior to the start of  
neratinib if the patient was taking any of these agents . If unavoidable, patients taking 
CYP3A4 inhibitors should be monitored closely.  
3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active 
infection , symptomatic congestive heart failure, unstable angina pectoris, cardiac 
arrhythmia, or psychiatric illness/social situations that would limit compliance with 
study requirements . 
4. Acute or currently active hepatic or biliary disease requ iring antiviral therapy (with the 
exception of patients with Gilbert’s syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per investigator assessment).  
5. Pregnant  and/or breastfeeding.  
6. History of significant cardiac disease,  cardiac risk factors, or uncontrolled arrhythmias.  
7. Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs 
resulting in dyspnea at rest.  
8. Experiencing grade 2 or greater diarrhea. 
9. Prior treatment with neratinib.  
10. Child -Pugh class B or  C liver dysfunction.  
 
3.3 Inclusion of Women and Minorities  
 
Both men and women and members of all races and ethnic groups are eligible for this trial . 
   
 
Version 03/16/2020 – Amendment 13   Page 26 of 87  
4.0 REGISTRATION PROCEDURES  
 
4.1 Pre-Registration  (for patients with unknown HER2 mutation status to have tumor  
tissue screened centrally by [CONTACT_193262] U GPS laboratory)  
 Patients must not start any protocol intervention prior to pre -registration through the 
Siteman Cancer Center.  All eligible and consenting patients will be  pre-registered to this protocol 
for the purpos es of HER2 sequencing;  if HER2 mutation is identified , the patient will then be 
registered if  eligible  for study treatment .  
 
The following steps must be taken:  
1. Confirmation of patient  pre-registration  eligibility by [CONTACT_2370]  
2. Pre-Registration  of patient in the Siteman Cancer Center database  
3. Assignment of unique patient number (UPN)   
 
Once the patient has been entered in the Siteman Cancer Center database, the WUSM coordinator 
will forward verification of enrollment and the UPN via email.  
 
4.1.1 Confi rmation of Patient Eligibility for Pre -Registration  
 
Confirm patient eligibility by [CONTACT_430940] ([EMAIL_8208]
) at least one  
business day prior to registering patient : 
 
1. Your name  [CONTACT_3669] [CONTACT_3031] ( telephone number, fax number, and email 
address ) 
2. Your site PI’s name, the registering MD’s name,  and your institution name  
3. Patient’s race, sex, and DOB  
4. Three letters (or two letters and a dash) for the patient’s initials  
5. Currently approved protocol version date  
6. Copy of signed consent form (patient name [CONTACT_205192])  
7. Planned date of sa mple shipment  
8. Completed pre-registration eligibility checklist (Appendix B), signed and dated by 
a member of the study team  
9. Copy of appropriate source documentation confirming patient eligibility  
 
4.1.[ADDRESS_544997]. Urgent 
late afternoon or early morning enrollments should be planned in advance and coordinated 
with the Washington University research coordinator.  R egistration wil l be confirmed by 
[CONTACT_205978]/her delegate by [CONTACT_430941]. Verification of eligibility and pre -registration should be kept in the patient chart.  
 Patients at all sites must be pre -registered through the Siteman Cancer Center OnCore 
database at Washington University.  
  
 
Version 03/16/2020 – Amendment 13   Page 27 of 87  
4.1.3 Assignment of UPN  
 
Each patient will be identified with a unique patient number (UPN) for this study.  Patients 
will also be identified by [CONTACT_22705], middle, and last initials.  If the patient has no middle initial, a dash will be used on the case report forms (CRFs).  All data will be recorded with this identification number on the appropriate CRFs. 
 
4.[ADDRESS_544998] HER2 mutation i n the tumor  will be 
registered to receive study therapy  if the patient remains eligible .  The same UPN will be used.    
 Patients with HER2 mutation identified by [CONTACT_430942].   An UPN will be assigned  as described in 
Section 4.1.3.  
 
4.2.1 Confirmation of Patient Eligibility for Registration  
 
Confirm patient eligibility by [CONTACT_430943] r Clinical Trials Core Protocol Procedures 
for Secondary Sites  packet  and email Caroline Bumb ([EMAIL_8208]
) at least two  
business day s prior to registering patient:  
 
1. Your name [CONTACT_3669] [CONTACT_3031] (telephone number, fax number, and email 
address)  
2. Your site PI’s name, the registering MD’s name, and your institution name  
3. Patient’s race, sex, and DOB  
4. Three letters (or two letters and a dash) for the patient’s initials  
5. Currently approved protocol version date  
6. Copy of signed consent form (patient name [CONTACT_205192])  
7. Planned date of treatment to start  
8. Completed registration eligibility checklist (Appendix C ), signed and dated by a 
member of the study team  
9. Copy of appropriate source documentation confirming patient eligibility  
 
4.2.[ADDRESS_544999]. Urgent late afternoon or early morning enrollments should be planned in advance and coordi nated 
with the Washington University research coordinator.  Registration will be confirmed by [CONTACT_205978]/her delegate by [CONTACT_430944]. V erification of 
eligibility and registration should be kept in the patient chart.  
 Patients at all sites must be registered through the Siteman Cancer Center OnCore database 
at Washington University. 
  
 
Version 03/16/2020 – Amendment 13   Page 28 of 87  
4.3 Recruitment through Army of Women  
 
The following proce dures describe how women recruited via Army of Women (AOW) will be 
screened and registered for this trial:  
 
1. HRPO- approved Eblast will be sent by [CONTACT_430945].  
2. Women responding to the Eblast will be referred by [CONTACT_430946] [EMAIL_8223] . 
3. WUSM study coordinator will send a HRPO -approved introductory email to each AOW 
recruit requesting a time to discuss the trial and attaching the version of the screening consent form drafted specifically for outside  recruits.  
4. WUSM study coordinator will consent the AOW recruit over the phone.  If the recruit consents to be screened for this trial, the WUSM study coordinator will mail the patient info sheet and a SASE, requesting that the patient complete the info sheet and return it along 
with the screening  consent form.  
5. Once the screening consent form and patient info sheet have been received by [CONTACT_430947], the medical records for the AOW recruit will be requested by [CONTACT_430948].  
6. Once the medical records have been received, th e pre -registration process described in 
Section 4.[ADDRESS_545000] 
a tumor specimen for HER2 mutation testing.  The WUSM study coordinator will send the report to the patient after reviewing with the PI.  If negative, the patient is not eligible to 
continue in the study.  If positive, the PI [INVESTIGATOR_430894]’s 
oncologist if the patient desires it and will refer the patient to a participating institution for 
consent to the main study. 
 
4.[ADDRESS_545001] information of the WUSM study 
coordinator will be made and distributed to medical oncologists from outside practices at scientific 
meetings and lectures.  These physicians will be encouraged t o refer potentially eligible patients to 
the WUSM study coordinator, who will begin the pre -registration screening process as described 
in #3 in Section 4.3.  Screening and testing will continue as described in Section 4.3.  
 
 
5.0 TUMOR HER2 SEQUENCING   
 
5.1 Tumor HER2 sequencing at Washington University CLIA lab following pre -
registration for eligibility  
 
Patients meeting the pre -registration eligibility criteria  with unknown tumor HER2  
mutation status  could  undergo tumor HER2  sequencing centrally  at the CAP/ CLIA certified 
Genomic and Pathology Services at Washington University (GPS@WU)  after pre -
registration to the study . Sanger sequencing of  Exons 18, 19, 20, 21, 22, 23 and 24 was 
initially used for the study.  Since October 2014, this was switched to a next  generation 
 
Version 03/16/2020 – Amendment 13   Page 29 of 87 sequencing ( NGS ) HER2 assay that covers  all coding exons of the HER2  gene.   
 
Archival tumor specimens from the primary breast cancer or from a metastatic site is required for the sequencing analysis.  Samples will be need to be shipped to the “Clinical 
Support Services Office at the Washington University Department of Pathology & 
Immunology” .  Please refer to the Correlative Science Procedures Manual Section  1.[ADDRESS_545002] access (requiring password) to a secur e 
folder on the WUSM pathology department network drive where the clinical reports are stored. For remotely screened participants, the reports will be faxed or emailed to the 
participant or the treating physician as applicable.  
 
5.2 Tumor or circulating tumor  DNA HER2 Mutation/Variants Identified at 
Laboratories other than GPS@WU   
 
Patients with tumor or circulating tumor DNA  HER2 mutations meeting the criteria defined 
in Section 5.3 identified at other CAP/CLIA -certified laboratories are eligible for study 
entry if they meet all other eligibility criteria.  To determine the eligibility of the reported 
mutation from laboratories other than Wash U GPS, the full report will need to be sent to 
Caroline Bumb ( [EMAIL_8208] ) and Cynthia Ma ( [EMAIL_4038]
). 
 
Pre-registration process is not required  for patients with known mutations as above  but the 
archival  tumor sample must be submitted to Wash U Alliance/ACOSOG- CSB/TPC , not to 
the Clinical Support Service Office , for future confirmation of the HER2  mutation and 
correlative studies  (also refer to the Section 10 for Correlative Study).  Please refer to the  
Correlative Science Procedure Manual regarding the sample requirement and shippi[INVESTIGATOR_430895] .     
 
5.3 Eligible HER2  mutations   
 
HER2  mutation is defined as a   single nucleotide variant (SNV) or  an indel variation that changes 
the encoded amino acid in the coding region of HER2  or an intronic mutation known to affect the 
splicing of HER2 . Identified SNVs  will be compared to known single nucleotide polymorphisms 
(SNPs)  identified in the SNP data base as well as to the variants identified  in cancer mutation 
databases including the Catalogue Of Somatic Mutations In Cancer (COSMIC) database.  HER2  
SNPs would be not considered as an HER2  mutation.  Germ -line DNA will be sequenced to rule 
out single nucleotide polymorphisms if needed.  
 All somatic HER2  mutations were eligible for Part  I of the trial.  However, due to the lack of 
response in patients with HER2  mutations of unknown significance observed in Part I of the trial 
[68], only known activating mutations listed in Table [ADDRESS_545003] will 
be assessed on a case -by-case basis by [CONTACT_43038] y team to determine eligibility.  
 
 
Version 03/16/2020 – Amendment 13   Page 30 of 87 Table 2   Known Activating HER2 Mutations  
HER2 mutation  Reference  
G309A/E  [56, 57] 
S310F/Y  [56] 
S653C  [58] 
L755S  [57, 59, 60] 
L755P  [60] 
Del. 755 -759 [57] 
D769Y/H  [57] 
V777L  [57, 60] 
V842I  [57] 
T862A  [60] 
L869R  [62] 
H878Y  [60, 63, 64] 
G776V/C  [65] 
All exon 20 insertions, including:  
A771_Y772insYVMA  
A775_G776insYVMA 
P780_Y781insGSP  [66, 67]  
 
5.4 Germline DNA S equencing for HER2  to determine eligibility  
 
In cases where it is unclear whether the identified HER2 variant is somatic (tumor specific) versus 
germline  in origin , the study team at WU SM will notify the site investigator to submit a blood 
sample of the patient for germline DNA sequencing at Wash U GPS laboratory. Please refer to Section 2.0 of the Correlative Science Proced ure Manual for the submission and shipment.  
 
5.5 HER2 Mutation Testing by [CONTACT_430949] -free DNA of 160 -180 
base pairs, which are  originated from the necrosis or apoptotic process of cancer cel ls.  Advances 
in the next generation sequencing (NGS) technology and digital genomic techniques support the 
clinical validity of cell- free circulating DNA (ctDNA) sequencing analysis to non -invasively 
identify actionable genomic alterations, monitor treatm ent response, and investigate resistance 
mechanisms [69].  ctDNA sequencing is  particularly helpful in cases  that tumor DNA sequencing 
is not possible due to insufficient  quality or quantity of the tumor tissue.   
 In collaboration with Guardant Health, Inc., we analyzed the plasma ctDNA collected from patients enrolled in this trial using the CLIA certified digital sequencing panel  (Guardant 360) , which 
utilizes hybrid capture followed by [CONTACT_430950] 30 genes  (including HER2)  and critical 
exons (those reported as having a somatic mutation in COSMIC) of [ADDRESS_545004] and report single nucleotide variants (SNVs) and small indels in [ADDRESS_545005] fusions  [70].  The plasma ctDNA sequ encing successfully 
identified HER2 mutation in 11/14 (79%; 90% CI: 53- 94%) patients  tested positive for HER2 
mutation by [CONTACT_430951]2.  Importantly, none of the 32 patients who were negative for HER2 mutation by [CONTACT_430952].  Therefore, the specificity of the Guardant 360 ctDNA sequencing for HER2 mutation was 100% (90% CI: 91-100%).  These data are being prepared for publication.  Based on these results and the fact that tumor DNA sequencing for HER2 was unsuccessful in over 25% of patients pre -registered to this 
 
Version 03/16/2020 – Amendment [ADDRESS_545006] HER2 non- mutant tumors  will also be used for studies to correlate HER2  mutation with 
histology subtype (invasive lobular vs. invasive ductal cancer), tumor grade (grade 1- 2 vs. 3), tumor 
staging at initial diagnosis (I vs. II or III vs. IV), and disease -free survival in HER2 -negative  breast cancer.  
The left over tumor speci mens from HER2 sequencing analysis from all patients will be assayed in future 
studies to understand the biology of HER2- negative  breast cancer.  The future studies could include tumor 
DNA, RNA or protein analysis.  
  
6.1 Neratinib  Administration  
 
Neratinib is administered in the outpatient setting.  It will be taken by [CONTACT_216359], preferably 
in the morning daily, starting at 240mg per day.  Neratinib will be given on a 28- day cycle (+/- 3 
days) .  The dose modification guideline s are provided in S ection 7.0.  In Cycle 2 or subsequent 
cycles, patients may begin taking 320mg per day of neratinib with prophylactic lopera mide 
provided the patients did not  experience  any intolerable grade 2 or higher treatment- related AEs 
during previous cycles (including diarrhe a while receiving prophylactic loperamide) .  
 
6.[ADDRESS_545007] be documented in the source 
documents.  Acceptable reasons are no n-tolerance of loperamide or lack of  efficacy .  Loperamide 
will be dispensed directl y by [CONTACT_430953] 1 (preferred option), or a prescription for loperamide 
will be provided for the subject with the instruction to have loperamide on hand prior to taking the first dose of investigational product.  If none of the above is feasible, the s ubject must obtain 
loperamide “ove r-the-counter” prior to taking the first dose of investigational product on D ay 1. 
 
6.3 Fulvestrant Administration  
 
Fulvestrant will be given on a 28- day cycle (+/ - 3 days).  It is administered at a dose of 500 mg (2 
x 250 mg injections) IM on Days 1 and 15 of Cycle 1, and 500 mg IM on Day 1 of each subsequent 
cycle.  Administer intramuscularly slowly in the buttock.  (NOTE: 500 mg dose will require one 250 mg injection in each buttock).  Immediately activate needle protection device upon withdrawal from patient by [CONTACT_430954].  Visually confirm that the lever arm has fully advanced and the needle tip is covered.  If unable to activate, discard immediately into an approved sharps container.  
 
6.4 General Concomitant Medication and Supportive Care Guidelines  
 
Patients should receive full supportive care, including transfusions of blood and blood products, antibiotics, antinausea/diarrhea, etc., when appropriate.  
 
 
Version 03/16/2020 – Amendment [ADDRESS_545008] -operative ly (no later than 3 weeks 
after holding it).  
 The start date and stop date and indication for concomitant treatments and/or therapi[INVESTIGATOR_430896] a n AE occurring from the signing of the consent form  until the end 
of treatment will be recorded on the Concomitant Medications F orm in REDCap . 
 
6.4.1 Prohibited Concomitant Treatment  
 
The following treatments are prohibited during neratinib therapy:  
• Any chemotherap y, radiation therap y, immunotherapy , biotherap y, or surgery  for 
breast  cancer.   
• Any other investigational agent.  
 
6.4.2 Permitted Concomitant Treatment during Neratinib Therapy  
 
The following treatments are permitted during the stud y: 
• Standard therapi[INVESTIGATOR_118477], and for medical and/or 
surgical complications.  All medication should be recorded.  
• Bisphosphonates, regardless of the indication.  
 
6.4.3 Addition of Trastuzumab  (or FDA Approved Biosimilar)  at Disease 
Progression on N eratinib  or Neratinib in combination with Fulvestrant 
 
If a patient experiences disease progression following neratinib or neratinib in combination 
with fulvestrant , trastuzumab may be added to the treatment regimen provided it is covered 
by [CONTACT_8130]’s  insurance company.  Trastuzumab has available biosimilar products FDA 
approved for use. Trastuzumab or any of the FDA approved commercially available 
biosimilar products for trastuzumab may be administered to patients based on their 
insurance requirements  or institutional practice. If a biosimilar product is required, dosing, 
schedule of administration, and premedications are identical to the guidance described throughout the protocol for trastuzumab. Preparation of the drug product will be dependent on the biosimilar selected for use.  
 Patients should start trastuzumab (or FDA approved bio similar) with their next scheduled 
fulvestrant injection. Neratinib does not need to be held between progression and Day 1 of trastuzumab (or FDA approved biosimilar) treatment. Palliative radiation for pain is 
allowed  prior to starting trastuzuamb with prior approval from the Washington University 
PI. Neratinib should be held during radiation.  AE monitoring, dose modification s for 
neratinib, and tumor response on combination therapy will be followed per protocol.  For 
these patients, treatment cycle will be restarted at cycle 1 at the start of trastuzumab.  Research blood collection  will follow the study calendar (beginning at C1D1).  
 
 
Version 03/16/2020 – Amendment 13   Page 33 of 87 Trastuzumab  (or FDA approved biosimilar) is administered intravenously with a loading 
dose of 6 mg/kg then 4 mg/kg every 2 weeks  +/- [ADDRESS_545009] (loading) dose of trastuzumab  (or FDA approved biosimilar) , premedication 
with diphenhydramine 50 mg PO or other antihistamine equivalent and acetaminophen 650 
mg PO will be given.  
 
  
  
 
Version 03/16/2020 – Amendment [ADDRESS_545010]  • Concomitant use of neratinib with a proton pump 
inhibitor (PPI, lansoprazole) resulted in a decrease 
of neratinib C max by 71% and AUC by 65%  
• Concomitant use with other pH lowering agents was 
not studied but a decrease in neratinib AUC is also considered likely  
• Decreased neratinib AUC may reduce neratinib 
activity  
Prevention or 
Management   
• PPIs 
  
Avoid concomitant use  
 
• H2-receptor antagonists  
  
Avoid concomitant use  
 
• Antacids  
  
Separate neratinib dosing 
by [ADDRESS_545011]  • Concomitant use of neratinib with a strong CYP3A4 
inhibitor (ketoconazole) increased neratinib C max by 
321% and AUC by 481%  
• Concomitant use of neratinib with other strong or 
moderate CYP3A4 inhibitors may increase 
neratinib concentrations  
• Increased neratinib concentrations m ay increase the 
risk of toxicity  
Preventation or 
Management  Avoid concomitant use of neratinib with strong or moderate 
CYP3A4 inhibitors.  
Examples1 Strong CYP3A4 inhibitors:   boceprevir, clarithromycin, 
cobicistat, conivaptan, danoprevir and ritonavir, diltiazem, 
elvitegravir and ritonavir, grapefruit juice, idelalisib, 
indinavir and ritonavir, itraconazole, ketoconazole, 
lopi[INVESTIGATOR_14475], nefazodone, nelfinavir, paritaprevir 
and ritonavir and (ombitasvir and/or dasabuvir), 
posaconazole, ritonavir, saquinavir and ritonavir, tipranavir 
and ritonavir, troleandomycin, voriconazole  
Moderate CYP3A4 inhibitors:  aprepi[INVESTIGATOR_053], cimetidine, 
ciprofloxacin, clotrimazole, crizotinib, cyclosporine, 
dronedarone, erythromycin, fluconazole, fluvoxamine, 
imatinib, tofisopam, verapamil  
Strong or Moderate CYP3A4 Inducers  
Clinical Impact  • Concomitant use of neratinib with a strong CYP3A4 
inducer (rifampin) reduced neratinib C max by 76% 
and AUC by 87%  
 
Version 03/16/2020 – Amendment 13   Page 35 of 87 • Concomitant use of neratinib with other strong or 
moderate CYP3A4 inducers may decrease neratinib 
concentrations  
• Decreased neratinib AUC may reduce neratinib 
activity  
Prevention or 
Management  Avoid concomitant use of neratinib with strong or moderate 
CYP3A4 inducers  
Examples1 Strong CYP3A4 inducers:  carbamazepi[INVESTIGATOR_050], enzalutamide, 
mitotane, phenytoin, rifampin, St. John’s wort  
Moderate CYP3A4 inducers:  bosentan, efavirenz, 
etravirine, modafinil  
1These examples are a guide and not considered a comprehensive list of all possible drugs that may fit this 
category.  Please contact [CONTACT_422028].  
  
If unavoidable, patients taking CYP3A4 inhibitors should be monitored closely.  
Subjects on coumarin- derivat ive anticoagulants (eg, warfarin) should be monitored closely 
and their anticoagulant dose adjusted as needed.   Subjects on chronic laxatives should be 
followed closely  and consideration should be given to decreasing or stoppi[INVESTIGATOR_430897], given the potential for neratinib- related diarrhea to be 
worsened by [CONTACT_430955].  Drugs known to cause QTc prolongation which are 
being given concomitantly require close monitoring of the subject with serial ECGs.  
 
MEDICATIONS THAT MAY CAUSE QTc PROLONGATION  
 
The following table presents a list of drugs that prolong, may prolong , or are unlikely to prolong the QTc. Please note that 
this list is frequently updated. For the most current list of medications, users should b e directed to the following website: 
http://www.azcert.org/medical -pros/drug -lists/drug -lists.cfm . 
 
Patients using drugs known to cause QT/QTc prolongation should be monitored closely with serial electrocardiograms (ECG) at the Investigator’s discretion.   
 
Compound  Compound Half Life  Possible 
Washout Period 
- Hours  Possible 
Washout 
Period - Days  
Alfuzocin  ~10 hours   7 
Amantadine  17 +/ - 4 hours (10 -25)  4 
Amiodarone (cordarone)  58 days (15 -142) 
36 days (active metabolite)   180 
Amitriptyline*  > 24 hours, wide interpatient variability    
Arsenic trioxide  Not characterized    
Azithromycin  40 hours    
Bepridil  42 hr (26 -64)  10 
Chloral hydrate  Readily converted to Trichloroethanol (active 
metabolite T 1/2=7-10 hour)  48  
Chloroquine  Prolonged (days to weeks)    
Chlorpromazine  30 +/ - 7 hours   7 
Cisapride  6 – 12 hour, up to 20 hour  60  
Clarithromycin  Non linear PK3 -4 hr (250mg Q12)  
5-7 hr (500mg Q12)  36  
Cloroquine  6 to 60 days; mean 20 days    
Desipramine*  > 24 hours, wide interpatient variability    
Disopyramide  6.7 hr (4 -10) 36  
Dofetilide  10 hr  48  
Dolesetron  8.1 hr    
 
Version 03/16/2020 – Amendment 13   Page 36 of 87 Domperidone  7-8 hr 48  
Doxepin*  > 24 hours, wide interpatient variability    
Droperidol  2.2 hours  10  
Erythromycin  * Each salt form has different Half life*    
Felbamate  20-23 hr   5 
Flecainide  20 hr (12 -27)  5 
Foscarnet  87.5+/ -41.8 hours  
*distribution and release from bone*   20 
Fosphenytoin  12-29 hr   6 
Gatifloxacin  7-14 hr  48  
Gemifloxacin  7 hours  48  
Grepafloxacin  16 hr   3 
Halofantrine  6-10 days ( variable among individual)   45 
Haloperidol  18 +/ -5 hr  5 
Ibutilide  6 hours (2 -12) * variable among subject*  36  
Imipramine*  > 24 hours, wide interpatient variability    
Indapamide  14 hours (biphasic elimination)   3 
Isradipi[INVESTIGATOR_050]  8 hours ( multiple metabolites)  48  
Levofloxacin  6-8 hours  48  
Levomethadyl  Multiple compartment PK with active metabolite  
2.6 day for LAAM, 2 day for nor -LAAM, 4 day for 
dinor -LAAM   20 
Lithium  24 hour (10 -50)  7 
Mesoridazine  24-48 hours ( animal study)   10 
Methadone  15-30 hours   7 
Moexipril/HCTZ  2-9 hour (include active metabolite) for moexipril; 
5.6-14.8 hours for HCTZ  48  
Moxifloxacin  12 +/ -1.3 hours  72  
Naratriptan  6 hours  36  
Nicardipi[INVESTIGATOR_050]  ~ [ADDRESS_545012] IV  infusion  12  
Nortriptyline*  > 24 hours, wide interpatient variability    
Octreotide  1.7 hours  12  
Ofloxacin  5 to 7.5 hours   2 
Ondansetron  4 hours (IV/IM); 3 hours (PO)   1 to 3  
Pentamidine  6.4+/ -1.3 hours  36  
Pi[INVESTIGATOR_3924]  55 hours   10 
Procainamide  3-4 hour for PA and NAPA (active metabolite)  24  
Protiptyline*  > 24 hours, wide interpatient variability    
Quetiapi[INVESTIGATOR_050]  6 hours  36  
Quinidine  6-8 hours in adult; 3 -4 hours in children  36  
Quinine  4-5 hours    
Risperidone  3-20 hours (extensive to poor metabolizer)  
9-hydroxyrisperidone (active metabolite) T ½ =21 -30 
hours (extensive to poor metabolizer)   4 
Salmeterol  5.5 hours ( only one datum)  36  
Sotalol  12 hours  72  
Sparfloxacin  20 hours (16 -30)  4 
Sumatriptan  2.5 hours  12  
Tacrolimus  ~34 hours in healthy; ~19 hours in Kidney transplant   7 
Tamoxifen  5-7 days (biphasic)   30 
Telithromycin  2-3 hr 24  
Thioridazine  20-40 hours (Phenothiazines)   7 
Tizanidine  2.5 hours  12  
Vardenifil  4 to 5 hours    
Venlaflaxine  5 +/-2 hours for parent comp.  
11+-2 hours for OVD (active metabolite)  60  
Voriconizole  6 hours; dose dependent    
Ziprasidone  7 hr 36  
 
Version 03/16/2020 – Amendment 13   Page 37 of 87 Zolmitriptan  2.8-3.7 hours (higher in female)  18  
*Weakly associated with Torsades de Pointes and/or QT prolongation but that are unlikely to be a risk for Torsades de Pointes when used in usual 
recommended dosages and in patients without other risk factors ( e.g., concomitant QT prolonging drugs, bradycardia, electrolyte disturbances, congenital 
long QT syndrome, concomitant drugs that inhibit metabolism) . 
 
References:  
1. Physician’s Desk Reference 2002  
2. Facts and Comparisons ( update to June 2005)  
3. The Pharmacological Basis of Therapeutics 9th Edition, 1996  
 
6.5 Women of Childbearing Potential  
 
Women of childbearing potential (women with regular menses, women  with amenorrhea, women 
with irregular cycles, women using a contraceptive method that precludes withdrawal bleeding, 
and w omen who have had a tubal ligation) are required to have a negative serum  or urine pregnancy 
test within [ADDRESS_545013] do se of neratinib .   
 Female and male patients (along with their female partners) are required to use two forms of acceptable contraception, including one barrier method, during participation in the study and for one month following the last dose of the neratinib . Men must agree and commit to use a barrier 
method of contraception while on treatment and for [ADDRESS_545014] be notified in order to facilitate 
outcome follow -up. 
 
6.6 Duration of Therapy  
 
If at any time the constraints of this protocol are considered to be detrimental to the patient’s health 
and/or the patient no longer wishes to c ontinue protocol therapy, the protocol therapy should be 
discontinued and the reason(s) for discontinuation documented in the case report forms.  In the absence of treatment delays due to adverse events, treatment  may continue until one of the 
following criteria applies:  
 
• Documented and confirmed disease progression  
• Death  
• Adverse event(s) that, in the judgment  of the investigator, may cause severe or permanent 
harm or which rule out continuation of study drug 
• Gener al or specific changes in the patient’s condition render the patient unacceptable for 
further treatment in the judgment  of the investigator  
• Suspected pregnancy  
• Serious non- compliance with the study protocol  
• Lost to follow -up 
• Patient withdraws consent  
• Inves tigator removes the patient from study  
• The Siteman Cancer Center decides to close the study  
 
Version 03/16/2020 – Amendment [ADDRESS_545015].  Patients 
removed from study for unacceptable adverse events will be followed until resolution or 
stabilization of the adverse event.  Patients will be followed through either review of m edical 
records, phone calls, or office visits.  
  
7.0 DOSE DELAYS/DOSE MODIFICATIONS AND AE MANAGEMENT  
 
7.1 Neratinib Dose Administration Table  
 
The allowed dose levels for dose reduction(s) due to toxicity which is deemed possibl y, 
probabl y, or definite ly related to  neratinib are listed in the below dose administration 
table.  
 
 
Dose Level  Neratinib (mg)  
 Number of 40 mg  
tablets  
2 320 8 
Starting dose  (1) 240 6 
-1 200 5 
-2 160 4 
-3 120 3 
 
7.2 General Dose Adjustments for Neratini b-Related Toxicities  
 
Dose escalation of neratinib to 320 mg per day with prophylactic lopera mide is allowed to start 
at Cycle 2 or subsequent cycles in patients who experienced no intolerable grade 2 or higher 
treatment- related AEs during the previous cycle (s) of therapy (inclu ding diarrhea while receiving 
prophylactic loperamide) .  The guideline for diarrhea management outlined in S ection 7.[ADDRESS_545016] fails to recover to NCI grade 0 to 1 (or to within baselin e of starting values for 
preexisting laboratory  abnormalities) from treatment- related toxicit y, leading to treatment delay of 
>3 weeks.  Misse d dose(s) of the investigational product will not be made up. Dose adjustments 
are described below.  Additional cl inical situations may result in dose adjustments as clinically 
indicated (e.g., intolerable, persistent grade 2 drug -related AE).  For genera l guidelines for the 
management of diarrhea, refer to Section 7.3.  The management of LFT changes is specifically  
addressed in Section  7.4.  For the management of LVEF declines, follow the guidelines in Section 
7.5. 
  
 
Version 03/16/2020 – Amendment 13   Page 39 of 87  
Event  
(Based on NCI CTC  4.0)  
Action  
Pneumonitis/Intersti tial Lung Disease:  
Symptomatic Grade  2 or Grade ≥3  • Symptomatic Grade 2: Hold the  
investigational product until resolution to ≤ 
grade [ADDRESS_545017] at the 
next lower dose level.  
• Grad e ≥3: Discontinue the  investigational 
product permanent ly. 
 
 Grade 4 (Hematologic or 
Nonhematologic)  
 
(Including nausea and/or vomiting despi[INVESTIGATOR_430898]) • Hold  the investigational product  until 
recovery to ≤grade [ADDRESS_545018] with 2 dose levels reduction.  
 
Other Grade 3 Nonhematologic 
(Including nausea and/or vomiting 
despi[INVESTIGATOR_430899], and 
asthenia lasting  
>3 days) • Hold the investigational product until 
recovery to ≤grade [ADDRESS_545019] at the next lower dose level.  
 
7.3 Guidelines for  the Management of Diarrhea  
 
Diarrhea is the major DLT of neratinib with onset typi[INVESTIGATOR_430900] (during the first few weeks of treatment).  Primary prophylactic use of antidiarrheal medication is mandatory for all enroll ed subjects  receiving neratinib at either 240mg or 320mg 
daily .  Loperamide is the recommended standard therapy to treat diarrhea in this study.  If 
alternative antidiarrheal medication is proposed, this should be discussed with the Principal Investigator  [INVESTIGATOR_430901]. Second- line antidiarrheal 
treatments and adjunctive therapi[INVESTIGATOR_014] (i.e., octreotide [SANDOSTATIN®]) are also recommended  
for use when appropriate . 
 The investigator must review with the subjec t the patient instructions  for the management of 
diarrhea and the Medication Diary (Appendix B) for the subject’s  daily recording of investigational 
product dose, any adverse reactions, number of stools and use of loperamide and/or other antidiarrheals.  Both the subjec t and the investigator must sign the IRB- approved patient 
instructions (template is Appendix C) for the management of diarrhea.  Copi[INVESTIGATOR_430902] D ay [ADDRESS_545020] the investigator in the event of de novo onset or persistent ≥  grade [ADDRESS_545021] be as precise as possible and captured in the Medication  Diary  (Appendix B).  For a dverse event recording, documentation of 
“Intermittent” events of diarrhea is limited to grade 1.  If events of grade 1 diarrhea are separated 
 
Version 03/16/2020 – Amendment [ADDRESS_545022] visit, details of the  daily number of unformed  
stools provided on the diary help to grade the diarrhea as precisely as possible (per  NCI CTC 4.0).  
Also, daily dose of loperamide (or other antidiarrheals, if applicable) noted on the diary will be reviewed and recorded on the C RF. 
 Loperamide will be dispensed directly by [CONTACT_779] (either as a script or from over the counter) on 
day [ADDRESS_545023] dose of neratinib to minimize occurrence a nd severity of diarrhea.  
 
Prophylactic dosing instructions  (Cycle s 1 and 2 ) 
• Inform patients that they will experience diarrhea while taking neratinib  
• Administer loperamide: initial dose of 4 mg (2 tablets/capsules) with the first dose of neratinib  
• For days  1 through 14, administer 4 mg (2 tablets/capsules) three times daily  
• For days 15 through 56, administer 4  mg (2 tablets/capsules) twice daily  
• If diarrhea occurs despi[INVESTIGATOR_430903], treat with additional antidiarrheals, fluids and electrolytes as clinical ly indicated . NERLYNX dose interruptions and dose reductions 
may also be required to manage diarrhea  
• For patients with persistent grade 1 diarrhea (<4 stools per day above baseline) on 
loperamide, Lomotil (diphenoxylate hydrochloride and atropi[INVESTIGATOR_52339]) 1 tablet (2.5 mg) 
every 6-8 hours may be added. 
• Prophylactic loperamide administration may continue for subsequent cycles at the 
physician’s discretion.  
• For grade 2 diarrhea during cycle 1 (4 to 6 stools per day above baseline, despi[INVESTIGATOR_430904]-diarrheal therapy as described above), consider adding octreotide (short -acting) 150 
micrograms SC TID; or after initial dose of short- acting octreotide, if well tolerated, a single 
dose of octreotide LAR 20 mg IM. 
 
For new onset uncomplicated grade 1 or grade 2 diarrhea  (in Cycle 2 and beyond)  
Dietetic measures  
• Stop all lactose -containing products  
• Drink 8 to 10 large glasses of clear liquids per day 
• Eat frequent small meals 
• Recommend low fat regimen enriched with bananas, rice, applesauce and toast (BRAT diet)  
until resolution of diarrhea.  
 
Pharmacological Treatment  
• For days 57 through 365, administer 4mg (2 tablets/capsules) as needed (not to exceed 8 
tablets capsules or 16 mg per day)  
• For patients with persistent grade 1 diarrhea on loperamide, Lomotil (diphe noxylate 
hydrochloride and atropi[INVESTIGATOR_52339]) 1 tablet  (2.5 mg)  every 6 hours to 8 hours may be added. 
• For grade 2 diarrhea  (4 to 6 stools per day above baseline, despi[INVESTIGATOR_430904] -diarrheal 
therapy), consider adding octreotide (short -acting) 150 micr ograms SC TID; or after initial 
dose of short -acting octreotide, if well tolerated, a single dose of octreotide LAR 20 mg IM. 
 
Version 03/16/2020 – Amendment 13   Page 41 of 87  
For grade 3 or grade 4 diarrhea with complicating features (dehydration, fever, and/or grade 
3-4 neutropenia  
Dietetic measures (same as above)  
Pharmacologic treatment  
• Administer loperamide: initial dose of 4 mg (2 tablets) with the first bout of diarrhea 
followed by 2 mg (1 tablet) every 4 hours or after every unformed stool (maximum 16 mg a day) and continue loperamide at this frequency until diarrhea free for 12 hours. Then titrate the amount of loperamide used to keep diarrhea controlled (< 4 stools/day).  
• Administer octreotide (SANDOSTAINE®) [100 -150 µg SC BID or IV (25- 50 µg/h) if 
dehydration is severe, with dose escalation up to 500 µg SC TID]  
• Use intravenous fluids as appropriate  
• Consider prophylactic antibiotics as needed (e.g., fluoroquinolones) especially if diarrhea is persistent beyond 24 hours or there is fever or grade 3- 4 neutropenia. 
 Stool cultures should be done to exclude infectious causes of grade 3 or 4 diarrhea or diarrhea of any grade with complicating features (dehydration, fever, and/or grade 3 or 4 neutropenia) per the investigator’s discretion.  Results from occult blood, fecal leukocyte stain, Clostridium difficile, Campylobacter, Salmonella, and Shigella testing, when performed, should be reported.    Subjects with significant diarrhea who are unresponsive to medical treatment may require treatment interruption or dose reduction.   
 
Gastrointestinal Toxicities Requiring Dose Adjustment of Neratinib  
NCI CTCAE V4.0  Action  
Grade 1 Diarrhea [Increase of < 4 stools per 
day over baseline; mild increase in ostomy 
output compared to baseline.]  
OR 
Grade 2 Diarrhea  [Increase of 4 -6 stools per 
day over baseline; moderate increase in ostomy 
output compared to baseline;]  lasting ≤ 5 days  
OR 
Grade 3 Diarrhea [Increase of ≥7 stools per day 
over baseline; incontinence; hospi[INVESTIGATOR_374]; severe increase in ostomy output compared to baseline limiting self -care activities 
of daily living {ADL};]  lasting ≤ 2 days  • Adjust anti -diarrheal treatment, as per the 
guidelines for management of diarrhea at the first onset of diarrhea.  
• Continue neratinib at full dose.  
• Instruct  patient to follow dietetic 
recommendations in the guidelines for 
management of diarrhea .  
• Fluid intake of ~2L should be maintained to avoid dehydration.  
• Once the event resolved to ≤ grade 1 or 
baseline, start loperami de 4 mg with each 
subsequent neratinib administration.  
Persisting and intolerable  Grade 2 Diarrhea  
lasting >5 days despi[INVESTIGATOR_430905],  or associated with 
fever, dehydration,  or grade 3 -4 neutropenia  
OR 
Grade 3 Diarrhea lasting > 2 days despi[INVESTIGATOR_430906], or • Adjust anti -diarrheal treatment, as per the 
guidelines for management of diarrhea  at the 
first onset of diarrhea.  
• Hold neratinib until recovery to ≤ grade 1 or 
baseline.  
• Instruct patient to follow dietetic recommendations of the guidelines for 
management  of diarrhea.  
 
Version 03/16/2020 – Amendment 13   Page 42 of 87 NCI CTCAE V4.0  Action  
associated with fever, dehydration,  or grade 3 -4 
neutropenia  
OR 
Any Grade 4 diarrhea  [Life -threatening 
consequences; urgent intervention indicated]  • Fluid intake of ~2L should be maintained, 
intravenously if needed.  
• If recovery occurs:  
o ≤1 week after withholding treatment, 
resume same dose of neratinib.  
o Within 1 -3 weeks after withholding 
treatment, reduce neratinib dose to the 
next lowe r dose level.  
• If event recurs and the neratinib dose has 
not already been decreased, reduce neratinib 
dose to the next lower dose level.  
• If subsequent events occur, reduce neratinib dose to the next lower dose level.  
• Once the event resolved to ≤ grade 1 or 
baseline, start loperamide 4 mg with each subsequent neratinib administration.  
• If event recurs and the neratinib dose has 
already been reduced at the lowest level, 
discontinue neratinib . 
 
7.[ADDRESS_545024] been reported in subjects taking neratinib.  Subjects experiencing grade 3 
or 4 diarrhea requiring IV hydration and associated with a ny signs or symptoms of hepatotoxicity 
such as worsening of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash 
or eosinophilia should be evaluated for LFT changes.  Abnormal values in aspartate transaminase (AST) and/or alanine transaminase (ALT) con current 
with abnormal elevations  in total bilirubin that meet the criteria in the table below in the absence  
of other causes of liver injury are considered potential cases of drug- induced liver injury (potential 
Hy’s Law cases) and should alway s be conside red important medical events.  
 The possibility of hepatic neoplasia (primary or secondar y) should also be considered.  
 During evaluation of potential hepatotoxicit y, bilirubin should be fractionated and prothrombin 
time should be measured.  Also, liver imaging should be obtained for subjects with any  signs or s ymptoms  of hepatotoxicity 
and/or grade 3 or greater LFT elevations, or as clinically indicated.  
     
    
 
Version 03/16/2020 – Amendment 13   Page 43 of 87  
 
Event  
(Based on NCI CTC4 .0)  
Action  
Grade 3 ALT (> 5-20x ULN), or 
Grade 4 ALT (>20x ULN), or  
Grade 3 Bili (>[ADDRESS_545025]) and direct bili ≥  
35% of total bili, or  
Grade 4 Bili (>10x ULN) and direct bili ≥  
35% of total bili.  • Permanently  discontinue 
investigational product (IP)  
• Evaluate alternative causes.  
ALT > 3x ULN and 
Total bilirubin > 2x U LN  and 
Alkphos < 2x U LN. • Hold  IP and immediate ly contact  [CONTACT_1600] [INVESTIGATOR_430907], including 
evaluation of alternative causes, and 
management  of IP. 
• Report as SAE.  
Signs or symptoms related to liver injury (abdominal 
pain, fever, jaundice, rash, eosinophilia, or drop in performance status) with either: 
 
Grade 2 ALT (>[ADDRESS_545026]), or  
Grade 2 ALT (>[ADDRESS_545027]) and  
Grade 2 Bili (>1.[ADDRESS_545028]) and direct bili  
≥ 35% of total bili.  • Permanently  discontinue IP.  
• Evaluate alternative causes.  
 
 
7.5 Guidelines for the Management of LVEF Declines 
 
LVEF assessments will be performed at the completion of every  four cycles during the treatment 
period.  It is strong ly recommended to use the same method of cardiac evaluation (ECHO or 
MUGA) at each time point for  each subject.  
 
In case of s ymptomatic heart failure,  the investigational product must be discontinued permanent ly. 
 
Asymptomatic decline in L VEF that warrants intervention is defined as:  
• LVEF < LLN  AND  absolute  decre ase in LVEF of ≥ 10% compared with pr e-treatment 
LVEF, OR  
• Absolute decrease in LVEF of  ≥ 15% compared with pr e-treatment LVE F 
 
If asymptomatic decline in LVEF that warrants intervention is experienced, then:  
• Temporari ly HOLD neratinib and  
• Repeat LVEF in 3 -4 weeks  
 If asymptomatic decline in LVEF as defined above persists, permanently discontinue neratinib, 
repeat LVEF in 3 -4 weeks and consider cardiology consult.   If LVEF recovers to ≥ LLN and 
absolute decrease in LVEF of resolves to < 15%, resume neratinib at the same dose, and resume 
LVEF monitoring per this protocol.  
 If a subject has a second epi[INVESTIGATOR_430908], permanent ly discontinue neratinib, repeat LVEF in 3 -4 weeks and consider cardiology  
consult.  
 
 
Version 03/16/2020 – Amendment 13   Page 44 of 87 Note that, for adverse events other than a symptomati c LVEF decline, if neratinib is held for > [ADDRESS_545029]  should be defaulted to 50%. 
 
7.[ADDRESS_545030] dosage  75% 
of the da ys in the treatment period to be compliant.  Dose adjustments must follow the  
recommendations in this section.  
 Site personnel will review subject -completed diaries at every  visit and will document  on drug 
accountability  forms provided to the sites.  Dose administration will be  recorded on sponsor drug 
accountability  forms.  
 
7.7 Fulvestrant Dose Modifications  
 
There are no planned dose modifications for fulvestrant.  Dosing may be modified or discontinued 
at the discretion of the treating physician.  
 
7.8 Trastuzumab (or FDA Approved Biosimilar) Dose Modifications  
 
There are no planned  dose modifications for trastuzumab (or FDA approved biosimilar) .  Dosing 
may be modified or discontinued at the discretion of the treating physician. 
 
 
8.[ADDRESS_545031] be recorded on the toxicity tracking case report form (CRF) with the 
exception of:  
• Baseline adverse events, which shall be recorded on the medical history CRF  
 
Refer to the data submission schedule in Section 12 for instructions on the collection of AEs in the EDC. The Washington University Human Research Protection Office (HRPO) requires that all events 
meeting the definition of unanticipated problem or serious noncompliance be reported as outlined in Section 8.1.[ADDRESS_545032] be reported.  
 Puma Biotechnology requires that all adverse events be r eported as outlined in Section 8.7. 
 
 
Version 03/16/2020 – Amendment 13   Page 45 of 87 8.1 Reporting to the Human Research Protection Office (HRPO) at Washington 
University  
 
Reporting will be conducted in accordance with Washington University IRB Policies.  
 Pre-approval of all protocol exceptions must be obtained prior to implementing the change.   
8.2 Reporting to the Quality Assurance and Safety Monitoring Committee (QASMC) at Washington University  
 The Spons or-Investigator (or designee) is required to notify the QASMC of any unanticipated 
problem involving risks to participants or others occurring at WU or any BJH or SLCH institution 
that has been reported to and acknowledged by [CONTACT_9077].  Unanticipated problems reported to HRPO and withdrawn during the review process need not be reported to QASMC.  
 QASMC must be notified within 10 days  of receipt of IRB acknowledgment via email to 
[EMAIL_167]
.  Submission to QASMC must include the MyIRB form and any supporting 
documentation sent with the form .   
 For events that occur at secondary sites, the Washington University Sponsor Investigator (or designee) is required to notify the QASMC within 10 days of Washington University not ification 
via email to [EMAIL_167].  Submission to QASMC must include either the myIRB form and supporting documentation or (if not submitted to myIRB) the date of occurrence, description of the event, whether the event is described in the currently IR B approved materials, the event outcome, 
determination of relatedness, whether currently enrolled participants will be notified, and whether 
the informed consent document and/or any study procedures will be modified as a result of this 
event.  
 
8.3 Secondary Si tes Reporting Requirements  
 
The research team at each secondary site is required to promptly notify the Washington University Sponsor -Investigator and designee of all serious adv erse events (refer to Appendix E ) within 1 
working day  of the occurrence of the event or notification of the secondary site’s PI [CONTACT_12581].  
This notification may take place via email if there is not yet enough information for a formal written report (using FDA Form 3500a (MedWatch) and Washington Universi ty’s cover sheet (Appendix 
G).  A formal written report must be sent to the Washington University Sponsor -Investigator and 
designee within 4 calendar days  (for fatal or life -threatening suspected adverse reactions) or 11 
calendar days  (for serious unexpect ed suspected adverse reactions) of the occurrence of the event 
or notification of the secondary site’s PI [CONTACT_12581].  
 The research team at a secondary site is responsible for following its site’s guidelines for reporting applicable events to its site’s IRB according to its own institutional guidelines.  The research team 
at Washington University is responsible for reporting all applicable events to the FDA, IBC, and 
Puma Biotechnology, Inc.  as needed.  
 Washington University pre -approval of all protocol exceptions must be obtained prior to 
implementing the change.  Local IRB approval must be obtained as per local guidelines.  Washington University IRB approval is not required for protocol exceptions occurring at secondary sites.  
8.4 Reporting to Secondary Sit es 
 
 
Version 03/16/2020 – Amendment 13   Page 46 of 87 The Washington University Sponsor -Investigator (or designee) will notify the research team at 
each secondary site of all reportable events that have occurred at other sites  within [ADDRESS_545033] both at Washington University and at other secondary sites, if 
applicable. Refer to Section 16.0 (Multicenter Management) for more information. 
 
8.[ADDRESS_545034] of the  study will comply with all FDA safety reporting requirements.  PLEASE NOTE 
THAT REPORTING REQUIREMENTS FOR THE FDA DIFFER FROM REPORTING 
REQUIREMENTS FOR HRPO/QASMC.  It is the responsibility of the Washington University 
principal investigator [INVESTIGATOR_430909]:  
 
• Report  any unexpected fatal or life -threatening suspected adverse experiences (Refer to Appendix 
E for definitions)  no later than 7 calendar days  after initial receipt of the information.    
  
• Report a suspected adverse reaction that is both serious and unexpe cted (S[LOCATION_003]R, 
refer to Appendix E ) no later than 15 calendar days  after it is determined that the 
information qualifies for reporting.  Report an adverse event (refer to Appendix E ) 
as a suspected adverse reaction only if there is evidence to suggest a causal 
relationship between the drug and the adverse event, such as:  
o A single occurrence of an event that is uncommon and known to be strongly associated with drug exposure  
o One or more occurrences of an event that is not commonly associated with drug exposure but is otherwise uncommon in the population exposed to the 
drug 
o An aggregate analysis of specific events observed in a clinical trial that 
indicates those events occur more frequently in the drug treatment group than in a concurre nt or historical control group  
• Report any findings from epi[INVESTIGATOR_9037], pooled analysis of multiple 
studies, or clinical studies that suggest a significant risk in humans exposed to the 
drug no later than 15 calendar days  after it is determined that the information 
qualifies for reporting.  
• Report any findings from animal or in vitro testing that suggest significant risk in 
humans exposed to the drug no later than 15 calendar days  after it is determined 
that the information  qualifies for reporting.   
• Report any clinically important increase in the rate of a serious suspected adverse 
reaction of that listed in the protocol or IB within [ADDRESS_545035] bear prominent identification of its contents (“IND Safety Report”) and must be transmitted to the review division in the Center for Drug Evaluation 
 
Version 03/16/2020 – Amendment 13   Page 47 of 87 and Research (CDER) or in the Center for Biologics Evaluation and Research (C BER) that 
has responsibility for review of the IND.  Relevant follow -up information to an IND safety 
report must be submitted as soon as the information is available and must be identified as 
such (“Follow -up IND Safety Report”).  
  
8.[ADDRESS_545036] be reported by [CONTACT_430956], Inc. as follo ws: 
 
For expedited reports, (Site) will send the MEDWATCH report to the Company no later than seven 
(7) days for initial life -threatening and death reports, and fifteen (15) days for all other initial or 
follow -up serious and unexpected suspected adverse r eaction (S[LOCATION_003]R)  as assessed by [CONTACT_430957] -Sponsor for causality and expectedness based on 
the adverse reaction table in the most current Investigator Brochure , from the time of receipt of the 
SAE by (Site).  For non- expedited reports (i.e., unrelated to study drugs or listed/expected event), 
(Site) will send the MEDWATCH report to the Company no later than thirty (30) days from the 
time of receipt of the SAE by (Site).  
 
By e-mail to [EMAIL_4481]
 
 
SAEs brought to the attention of the investigator at any time after cessation of neratinib  and 
considered by [CONTACT_430958], Inc. if and when they occur. Additionally, in order to fulfill international 
reporting obligations, SAEs that are related to study participation (e.g., procedures, invasive tests, change s from existing therapy) or are related to a concur rent medication will be collected and 
recorded from the time the subject consents to participate in the study until he/she is discharged  
from the study . 
 
8.[ADDRESS_545037] day of study treatment. 
  
9.0 PHARMACEUTICAL INFORMATION  
 
9.1 Neratinib  
 
9.1.1 Description   
 
Neratinib (PB -272) is a potent irreversible pan erbB inhibitor.  Neratinib is an orall y 
available small molecule that inhibits erb B-1, erbB-2, and erbB -4 at the intracellular 
tyrosine kinase domains, a mechanism of action that is different from trastuzumab.  
 
 
Version 03/16/2020 – Amendment 13   Page 48 of 87 9.1.2 Clinical Pharmacology  
 
Please refer to section 1.2.3.  
 
9.1.3 Supplier(s)  
 
Neratinib will be provided free of charge by [CONTACT_227046], Inc .   
 
9.1.[ADDRESS_545038] is not allowed.  
 
9.1.5 Storage  and Stability  
 
Investigational products will be stored by [CONTACT_430959] a secure location at the storage con ditions 
listed on the label; store  at 25°C (77°F)  or below with desiccant (bottle contains the 
dessicant ); do not freez e.  Correspondingl y, subjects must be instructed to store 
investigational products in a safe place at these same storage conditions.  Sto rage in a 
refrigerator or cold room is acceptable as long as the temperature remains above 0 °C. 
 
The investigational product must be stored as indicated.  Deviations from the storage 
requirements, including any actions taken, must be documented and reported to the sponsor. 
Once a deviation is identified, the investigational product must be quarantined and not used 
until the sponsor provides documentation of permission to use the investigational product.  
 
The investigational product is only  to be administered to subjects who have provided 
informed consent.  Once the investigational product has been assigned to a subject it must not be reassigned to another subject.  
 
9.1.[ADDRESS_545039] will be taken by [CONTACT_216359], 
preferab ly in the morning. 
 
9.1.7 Special Handling Instructions  
 None. 
 
9.2 Fulvestrant  
 
9.2.1 Description  
 
Fulvestrant (Faslod ex) is an estrogen receptor antagonist which down- regulates the ER 
protein in breast cancer cells.  
 
9.2.2 Availability  
 
 
Version 03/16/2020 – Amendment 13   Page 49 of 87 Fulvestrant injection is commercially available as a sterile single- patient pre -filled syringe 
containing 250 mg at a concentration of 50 mg/ml. The solution is a clear, colorless to 
yellow, viscous liquid. In addition to the fulvestrant, each injection contains as inactive ingredients alcohol, USP, benzyl alcohol, NF, and benzyl benzoate, USP as co- solvents and 
castor oil, USP as a co -solve nt and release rate modifier.  
 
For patients who cannot obtain fulvestrant commercially, such as those who are without medical insurance or with a limited income, [COMPANY_008] Foundation Patient Assistance Program can be reached at 1 -[PHONE_8960] or by [CONTACT_430960] a PDF application from the 
[COMPANY_008] US web site at www.astrazeneca -us.com. Completed applications should be 
mailed to:  
[COMPANY_008] Foundation Patient Assistance Program  
[PO_BOX] St. Louis, MO [ZIP_CODE]- [ZIP_CODE] 
 
9.2.3 Storage and Stability  
 
The syringes of fulvestrant for all cycles of treatment should be stored in the original 
container and refrigerated at 2° - 8°C (36°-  46°F).  
 
9.2.4 Preparation  
 
Remove glass syringe barrel from tray and check that it  is not damaged. Peel open the s afety 
needle (SafetyGlide™) o uter packaging. Break the seal of the white plastic cover on the 
syringe luer connector to remove the cover with the attached rubber tip cap. Twist to lock 
the needle to the luer connector. Remove needle sheath. Remove excess air from the syringe 
(a small gas bubble may remain). 
 
9.2.5 Administration  
 
Fulvestrant will be administered at a dose of 500 mg (2 x 250 mg injections) IM on  Cycle 
1 Day 1 and Day 15, then on Day 1  of each subsequent cycle.  Administer intramuscularly 
slowly in the buttock. (NOTE: 500 mg dose will require one 250 mg injection in each 
buttock.) Immediately activate needle protection device upon withdrawal from patient by 
[CONTACT_430961]. Visually confirm 
that the lever arm has fully advanced and the needle tip is covered. If unable to activate, 
discard immediately into an approved sharps container.  
 
9.2.[ADDRESS_545040] the metabolism of 3A4 substrates. Thus, fulvestrant is not expected to be involved in significant drug interactions mediated by [CONTACT_097]3A4.  
 
Version 03/16/2020 – Amendment 13   Page 50 of 87  
 
10.0 CORRELATIVE STUDIES  
 
10.1 Required a rchival tumor sample for research:   
 
• Archival tumor specimens that are left over from the HER2 mutation analysis at 
Wash ington  University  are not returned and will be used for investigations of potential 
therapeutic targets in HER2 -negative breast cancer.   
• Additional archival tumor specimens may be requested for studies that compare mutations 
in primary versus metastatic disease sites, and predictors of treatment response to neratinib.  
• For patients who had HER2  mutation identified in a nother laboratory  and registered to the 
study, please submit archival tumor specimens to Wash U Alliance/ACOSOG -CSB/TPC.   
• Please refer to the Correlative Science Procedure  Manual Section 3.[ADDRESS_545041] HER2  mutation and are re gister ed 
to receive  study drug therapy.  Blood will be collected at baseline, during therapy as well as at 
disease progression  (Also refer to the Correlative Science Calendar  Section 10.5) , for ctDNA  
sequencing  and other circulating markers that may affect disease outcome.  Please ship samples 
to Wash U Alliance/ACOSOG- CSB/TPC.   
 
Please refer to the Correlative Science Procedure  Manual Section 3.2 for sample requirement and 
shippi[INVESTIGATOR_3931].  
 
10.3 Optional research tumor biopsy  (kits will be provided):  
 
If a patient is  registered to this  trial to receive neratinib and has  tumors that are safe for biopsy, 
we encourage  consenting for tumor collectio n prior to study drug administration and/or  at the 
time of disease progression on neratinib for investigations  that assess predictors of response to 
therapy and mechanisms of resistance.  
 
Note that the tumor biopsy collected at  disease progression on study treat ment will be subjected to 
the CLIA NGS panel of 122 genes  (the Comprehensive Cancer Gene Set, verion 3.2 (CCGSv3.2) ), 
at the Wash U GPS and a clinical report will be issued  to the site investigator to provide to the  
treating physician and the patient  within 3 -4 weeks of receiving the specimen.  The sequencing 
report will provide interpretations of genomic findings, but it is at the discretion of the treating 
physician and the patient in regards to any need for referral to clinical genetic counseling service.  The report may be helpful in assessing patient eligibility for clinical trials that require mutation screening.  
 Please refer to the Correlative Science Procedure Manual Section 3.3 in regards to sample 
requirements and shippi[INVESTIGATOR_3931].  
10.4 Reporting of a CLIA multi -gene NGS  on tumor biopsy collected at disease 
progression  on study drug :  
 
 
Version 03/16/2020 – Amendment [ADDRESS_545042] (WU Anatomic and Molecular Pathology Core lab), extraction of 
DNA, NGS library preparation and sequencing, NGS data analysis and variant interpre tation for 
the CCGSv3.2 Solid Tumor gene set (122 genes) . Cases with negative results (no level 1 or 2 
variants identified) will proceed to additional reflex testing for the hematopoietic disorders gene set (54 genes).  
 
10.5 Correlative Science Study Calendar 
 
Specimen Type  Collection/Submission Time Point  Shippi[INVESTIGATOR_430910]-
registration  Pre-
treatment / 
C1D1  (prior 
to starting 
treatment)  C1D15, C2D1, 
C3D1 and day 
1 of each odd 
cycle  EOT  / 
Prog  
Archival Tissue for HER2 
mutation testing (see  CSPM  
1.0) X    Ambient  GPS 
10 ml Whole Blood in EDTA 
for germline DNA sequencing 
(see CSPM  2.0) X1    Ambient  GPS 
Archival Tissue for correlative 
studies (See CSPM 3.0)  X2   Ambient  TPC 
10 ml Whole Blood in EDTA 
tube  X   Ambient  TPC 
3 ml plasma (from 10 ml 
EDTA tube)   X X X Frozen3 TPC 
3 ml serum (from [ADDRESS_545043] 
tube)   X X X Frozen3 TPC 
(2) 8 ml Streck tubes   X X X Ambient  TPC 
Optional Fresh Biopsies (see 
CSPM 3.3)  X  X Frozen and 
Ambient  TPC 
1 Only required if notified by [CONTACT_430962]  
2 FFPE tumor ric h block/slides  are required – due within 60 days of registration for patients who receive treatment on trial.  
3Store frozen samples at -70oC to -80oC.  Ship frozen samples quarterly on dry ice.  
CSPM:  Correlative Science Procedure Manual  
 
 
 
 
Version 03/16/2020 – Amendment 13   Page 52 of 87 11.0 STUDY CALENDAR  
 
Evaluations for pre -registration should be conducted within 8 weeks prior to pre -registration and specimen submission.  Evaluations for 
registration should be conducted within 2 weeks prior to registration, with the following exceptions: echocardiogram, scans, and x -rays, which 
should be performed within 4 weeks of registration. Study drug therapy should start within 7 days of registration.   
Screening Through Cycle 1  
 Pre-ScreeningW  
-56 to 0 days  
Pre-Registration  Screening  
-14 to 0 days 
unless otherwise 
noted  
Registration  C1D1  
(- 7) C1D2  C1D3  C1D4  C1D8  
(+/- 1) C1D15  
(+/- 1) C1D22  
(+/- 1) 
Informed Consent  X XV        
Medical History  X X        
Physical Exam w/ECOG  XI X X    X X X 
Vital SignsA  X X    XL XL XL 
Safety Phone CallK    X X X    
Adverse Events    X----------------------------------------------------------------- X 
CBC w/Differential  X X XM       
Blood Chemistry  X X XM       
Pregnancy TestH  X        
Blood for ResearchS   X     X  
ECG   X        
Echocardiogram or MUGAC  XE        
Tumor Assessment (CT or MRI)D  XE        
Tumor Biopsy (optional)   XO        
Archival Tumor  XU XT        
HER2 Mutation Report  XB        
Patient Instructions for Diarrhea 
Management (Appendix C)   X       
NeratinibN   X----------------------------------------------------------------- X 
FulvestrantN, R    X     X  
Medication Diary  (Appendix B)   X----------------------------------------------------------------- X 
Concomitant Medications   X X----------------------------------------------------------------- X 
Serious Adverse Events  XJ XJ X----------------------------------------------------------------- X 
  
 
Version 03/16/2020 – Amendment 13   Page 53 of 87 Cycle 2 Through End of Study  
 C2D1  
(+/- 3) C3D1  
(+/- 3) Day 1 of 
Subsequent 
Even Cycles 
(+/- 3) Day 1 of 
Subsequent 
Odd Cycles  
(+/- 3) End of 
Treatment  
(+ 7)  30 Day Follow 
Up 
(+/- 3) 
Physical Exam w/ECOG  X X X X X  
Vital Signs X X X X X  
Adverse Events  X------------------------------------------------------------------------------------------------ X 
Follow Up Phone Call       X 
CBC w/Differential  X X X X X  
Blood Chemistry  X X X X X  
Blood for ResearchS X X  X   
Tumor Assessment (CT or MRI)D  XF  XF   
Tumor Biopsy (optional)      XP  
Medication Diary (Appendix B)       
NeratinibG X------------------------------------------------------------------------------ X  
FulvestrantR X X X X   
Trastuzumab (or FDA approved biosimilar)Q  X---------------------------------------- X   
Concomitant Medications  X------------------------------------------------------------------------------------------------ X 
Serious Adverse Events  X------------------------------------------------------------------------------------------------ X 
A:  Height to be recorded only at baseline  
B:  The sequencing report identifying the eligible HER2 mutation is required.  
C:   Pre-registration and HER2 mutation testing, ECHO or MUGA is not required, but a patient with a known recent LVEF < LLN or with symptoms of congestive heart 
failure is not eligible for Pre -registration and HER2 mutation testing. ECHO or MUGA is required for all patients continuing t o the treatment portion of the trial.  
D:   CT of the chest, abdomen and pelvis with contrast is required for the study. If contrast could not be administered, CT of the  chest without contrast, and MRI of abdomen 
and pelvis would be acceptable. The same met hod should be used at each evaluation. Patients with skin lesions should have photographs taken at baseline and each 
evaluation. Please have a CD copy of each radiology assessment at the completion of the exam or upload the image in the “drop box” specifie d in the secondary site 
instructions. Please use either the tumor measurement form in Appendix D for RECIST 1.[ADDRESS_545044] 1.1 report for upload to the 
EDC.  
E:   Within 28 days prior to Registration.  
F: Radiology test f or tumor response assessment is to be performed at baseline and every  2 cycles  (+/- 7 days).  
G: Neratinib  is to be self -administered daily  on each day of every 28 -day cycle  (+/- 3 days) .  Please see Section 6.1 for dosing instructions.  
H: Premenopausal women of childbearing potential only  
I: Only performance status is required  
J:  Determined to be related to screening procedures.  
K: Safety calls to the patient are to be conducted 24, 48, and [ADDRESS_545045] dose administration and can be performed by [CONTACT_2420].  
L: Phys ical exam on C1D8, C1D15, and C1D22 may be performed by [CONTACT_430963].  
M:   Cycle 1 Day 1 labs do not need to be repeated if done within 7 days of treatment.  
 
Version 03/16/2020 – Amendment 13   Page 54 of 87 N: To accommodate calls to patients at 24, 48, and [ADDRESS_545046] dose of neratinib  +/- fulvestrant  could be started any time within one week following 
the C1D1 visit.  
O: Optional b aseline biopsy must be performed within 4 weeks before C1D1 or on C1D1 prior to starting neratinib +/ - fulves trant.   Please refer to Correlative Science 
Procedure Manual 
P: The biopsy at progression must occur prior to starting the next line of cancer therapy.   Note that a clinical sequencing report will be provided to the treating physician in 
3-4 weeks from Was h U.  Please refer to the Correlative Science Procedure Manual.  
Q: May be administered if patient progresses on neratinib +/ - fulvestrant; refer to Section 6.4.3 for dosing and schedule.  The +/- 3 day window applies to all treatment days.  
Trastuzumab or any of the FDA approved commercially available biosimilar products for trastuzumab may be administered to patients based on the ir insurance 
requirements or institutional practice.  
R:  In Part II ER+ cohorts, fulvestrant will be administered at a dose of 500 mg (2 x 250 mg injections) IM on Days 1 and 15 of Cycle 1, then on Day 1 of each subsequent 
cycle.  Please see Section 6.3 for dosing instructions.   Patients already on fulvestrant 500mg every 28 days prior to registration to the fulvestrant -treated cohort  do not 
need to receive the loading dose on C1D15.  In these patients, it is acceptable that C1D1 neratinib does not coincide with fulvestrant administration schedule per discretion of treating physician.  
S: Research blood is collected at baseline, on Cycl e 1 day 15, Cycle 2 day 1, on Cycle 3 Day 1, followed by [CONTACT_2006] 1 of every other cycles (including Cycles 5, 7, etc), and 
EOT.   Please refer to Correlative Science Procedure Manual.  
T: Due within 60 days of Registration . If sample was submitted for HER2 seque ncing after pre -registration a new block may not be required. See Correlative Science 
Procedure Manual.  
U:   See Correlative Science Procedure Manual for instructions for submitting archival tissue for HER2 sequencing  
V:   Consent can be obtained earlier than the 14 day screening window  
W: Patients with known HER2 mutations (see Section 5.2) are not required to complete pre -screening and pre- registration.  
 
 
Version 03/16/2020 – Amendment 13   Page 55 of 87 12.0 DATA SUBMISSION SCHEDULE 
 
Case report forms with appropriate source documentation will be completed within 60 days of the schedule 
listed in this section.  
 Electronic data management systems will be used in this trial in collaboration with the Institute for 
Informatics (I
2) at Wash ington University.  REDCap  is a web -based clinical studies data management 
system that will be used for capture of clinical data from this trial.   The case report forms developed for 
this trial will be transformed to electronic format. An electronic study calendar will drive the study’s data collection workflow.  E ach center has access only to data from its own participants.  Washington 
University, as the data coordinating center, has access to data from all sites.   Contact [CONTACT_430964] i nstructions on how to request access.  
 
Case Report Form  Submission Schedule  
Only for patients being screened for HER2 mutation 
at Washington University 
Pre-registration Consent Form  
Pathology Source Documents  
 Prior to HER2 mutation testing  
(send to main site registrar to confirm eligibility)  
Biospecimen Submission Form ( CSPM Appendix 2 ) 
GPS Submission Form ( CSPM Appendix 1) Sent with t umor s ample  
Biospecimen Submission Form ( CPSM Appendix 2) Sent with peripheral blood  
Consent Form  
Pathology Source Documents (only for patients who were previously screened for HER2 mutation at outside location)  
Eligibility Checklist  Prior to starting treatment 
Within REDCap  
Pre-Study Form  
Prior Therapy Form  
Vital Signs Form  
CBC Form  
Chemistries Form  
Tissue Collection Form  Enter p rior to treatment start  
Vital Signs Form  
CBC Form  
Chemistries Form  
Treatment Form  Enter within 2 week of the e nd of each  
cycle  
Peripheral Blood Collection Form  Due within 2 weeks of collection  
Toxicity Form  
Concomitant Medications  Form  Continuous  
Treatment Summary Form  Completion of treatment  
Follow Up Form  30 Day follow up  
Tumor Measurement Form  Baseline  
End of every other  cycle 
End of treatment  
MedWatch Form  See Section 8.0 for reporting requirements  
 
 
Version 03/16/2020 – Amendment [ADDRESS_545047] – Solid Tumors  
 
For the purposes of this study, patients should be re -evaluated for response every 8 weeks (2 
cycles) .   
 
Response and progression will be evaluated in this study using the new international criteria proposed by [CONTACT_459] (RECIST) guideline (version 1.1).  Changes in the largest diameter (unidimensional measuremen t) of the tumor lesions 
and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria.  
 
13.2 Disease Parameters  
 
Measurable disease:  Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >[ADDRESS_545048] x -ray, as >[ADDRESS_545049] scan, or >[ADDRESS_545050] be recorded in millimeters (or decimal fractions of centimeters).  
 Tumor lesions from a previousl y irradiated area may only be used as index lesions if they have 
demonstrated clear progression since completion of the radiation.  Malignant lymph nodes :  To be considered pathologically enlarged and measurable, a lymph 
node must be >[ADDRESS_545051] scan (CT scan slice thickness 
recommended to be no greater than 5 mm).  At baseline and in follow -up, only the short axis will 
be measured and followed.  Non-measurable disease:   All other lesions (or sites of disease), including small lesions (longest 
diameter <10 mm or pathological lymph nodes with ≥10 to <15 mm short axis), are considered non-measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonitis, inflammatory br east disease, and abdominal masses (not 
followed by [CONTACT_462]), are considered as non- measurable.  
 
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not be 
considered as malignant lesions (neither measurable nor non- measurable) since they are, by 
[CONTACT_108], simple cysts.  
 ‘Cystic lesions’ thought to represent cystic metastases can be considered as measurable lesions, if they meet the definition of measurability described above. However, if non- cystic lesions are 
present in the same patient, these are preferred for selection as target lesions.  
 Target lesions:  All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in 
total, representative of all involved organs, should be identified as target lesions and recorded and measured at baseline.  Target lesions should be selected on the basis of their size (lesions with the 
 
Version 03/16/2020 – Amendment [ADDRESS_545052] diameter), be representative of all involved organs, but in addition should be those that 
lend themselves to reproducible  repeated measurements.  It may be the case that, on occasion, the 
largest lesion does not lend itself to reproducible measurement in which circumstance the next largest lesion which can be measured reproducibly should be selected.  A sum of the diameters (longest for non- nodal lesions, short axis for nodal lesions) for all target lesions will be calculated 
and reported as the baseline sum diameters.  If lymph nodes are to be included in the sum, then only the short axis is added into the sum.  The baseline  sum diameters will be used as reference to 
further characterize any objective tumor regression in the measurable dimension of the disease.  
 Non-target lesions :  All other lesions (or sites of disease) including any measurable lesions over 
and above the 5 target lesions should be identified as non- target lesions and should also be recorded 
at baseline.  Measurements of these lesions are not required, but the presen ce, absence, or in rare 
cases unequivocal progression of each should be noted throughout follow -up.  
 
13.3 Methods for Evaluation of Measurable Disease 
 
All measurements should be taken and recorded in metric notation using a ruler or calipers.  All baseline ev aluations should be performed as closely as possible to the beginning of treatment and 
never more than 4 weeks before the beginning of the treatment.  The same method of assessment and the same technique should be used to characterize each identified and r eported lesion at baseline and during follow -up. Imaging- based evaluation is 
preferred to evaluation by [CONTACT_460](s) being followed cannot be imaged but are assessable by [CONTACT_461].  
 
Clinical lesions:  Clinical lesions will  only be considered measurable when they are superficial 
(e.g., skin nodules and palpable lymph nodes) and ≥ 10 mm diameter as assessed using calipers 
(e.g., skin nodules).  In the case of skin lesions, documentation by [CONTACT_6775], including a ruler to estimate the size of the lesion, is recommended.  
 Chest x -ray:  Lesions on chest x- ray are acceptable as measurable lesions when they are clearly 
defined and surrounded by [CONTACT_6776].  However, CT is preferable.  
 Conventional CT and MRI:   This guide line has defined measurability of lesions on CT scan 
based on the assumption that CT slice thickness is [ADDRESS_545053] slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice the slice thickness.  MRI is  also acceptable in certain situations (e.g. for body scans).   
 Use of MRI remains a complex issue.  MRI has excellent contrast, spatial, and temporal resolution; however, there are many image acquisition variables involved in MRI, which greatly impact im age 
quality, lesion conspi[INVESTIGATOR_3934], and measurement.  Furthermore, the availability of MRI is variable globally.  As with CT, if an MRI is performed, the technical specifications of the scanning sequences used should be optimized for the evaluation of the type and site of disease.  Furthermore, as with CT, the modality used at follow -up should be the same as was used at baseline and the 
lesions should be measured/assessed on the same pulse sequence.  It is beyond the scope of the RECIST guidelines to prescribe  specific MRI pulse sequence parameters for all scanners, body 
parts, and diseases.  Ideally, the same type of scanner should be used and the image acquisition protocol should be followed as closely as possible to prior scans.  Body scans should be perform ed 
with breath -hold scanning techniques, if possible.  
 
Version 03/16/2020 – Amendment [ADDRESS_545054]:  At present, the low dose or attenuation correction CT portion of a combined PET -CT 
is not always of optimal diagnostic CT quality for use with RECIST measurements.  However, if the site can do cument that the CT performed as part of a PET -CT is of identical diagnostic quality 
to a diagnostic CT (with IV and oral contrast), then the CT portion of the PET -CT can be used for 
RECIST measurements and can be used interchangeably with conventional CT i n accurately 
measuring cancer lesions over time.  Note, however, that the PET portion of the CT introduces additional data which may bias an investigator if it is not routinely or serially performed.    Ultrasound:   Ultrasound is not useful in assessment o f lesion size and should not be used as a 
method of measurement.  Ultrasound examinations cannot be reproduced in their entirety for independent review at a later date and, because they are operator dependent, it cannot be guaranteed that the same techniqu e and measurements will be taken from one assessment to the 
next.  If new lesions are identified by [CONTACT_12153], confirmation by [CONTACT_12154].  If there is concern about radiation exposure at CT, MRI may be used instead of  
CT in selected instances.  
 Endoscopy, Laparoscopy:   The utilization of these techniques for objective tumor evaluation is 
not advised.  However, such techniques may be useful to confirm complete pathological response when biopsies are obtained or to deter mine relapse in trials where recurrence following complete 
response (CR) or surgical resection is an endpoint.  Tumor markers:   Tumor markers alone cannot be used to assess response.  If markers are initially 
above the upper normal limit, they must normalize for a patient to be considered in complete clinical response.  Specific guidelines for both CA -125 response (in recurrent ovarian cancer) and 
PSA response (in recurrent prostate cancer) have been published [JNCI 96:487- 488, 2004; J Clin 
Oncol 17, 3461- 3467, 1999; J Clin Oncol 26:1148- 1159, 2008].  In addition, the Gynecologic 
Cancer Intergroup has developed CA -[ADDRESS_545055] -line trials in ovarian cancer [JNCI 92 :1534- 1535, 2000].  
 Cytology, Histology:   These techniques can be used to differentiate between partial responses 
(PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor types, such as germ cell tumors, where known residual benign tumors can remain).  
 The cytological confirmation of the neoplastic origin of any effusion that appears or worsens during treatment when the measurable tumor has met criteria for response or stable disease is mandatory to differentiate between response or stable disease (an effusion may be a side effect of the treatment) and progressive disease.  
 FDG -PET:   While FDG -PET response assessments need additional study, it is sometimes 
reasonable to incorporate the use of FDG -PET scanning to complement CT scanning in assessment 
of progression (particularly possible 'new' disease).  New lesions on the basis of FDG -PET imaging 
can be identified according to the following algorithm:  
 
• Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD 
based on a new lesion.  
• No FDG- PET at baseline and a positive FDG -PET at follow -up:  If the positive FDG -PET 
at follow -up corresponds to a new site of disease confirmed by [CONTACT_4654], this is PD.  If the 
positive FDG -PET at follow -up is not confirmed as a new site o f disease on CT, additional 
 
Version 03/16/2020 – Amendment [ADDRESS_545056]  scans are needed to determine if there is truly progression occurring at that 
site (if so, the date of PD will be the date of the initial abnormal FDG -PET scan).  If the 
positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT that is 
not progressing on the basis of the anatomic images, this is not PD. 
• FDG- PET may be used to upgrade a response to a CR in a manner similar to a biopsy in 
cases where a residual radiographic abnormality is thought to represent fibrosis or scarring.  
The use of FDG -PET in this circumstance should be prospectively described in the protocol 
and supported by [CONTACT_4623] -specific medical literature for the indication.  However, it must 
be acknowledged that both approaches  may lead to false positive CR due to limitations of 
FDG- PET and biopsy resolution/sensitivity.  
  
Note:  A ‘positive’ FDG -PET scan lesion means one which is FDG avid with an uptake greater 
than twice that of the surrounding tissue on the attenuation correc ted image. 
 
13.4 Response Criteria  
 
13.4.1 Evaluation of Target Lesions  
 
Complete Response (CR):   Disappearance of all target lesions.  Any pathological lymph 
nodes (whether target or non- target) must have reduction in short axis to <10 mm.  
 Partial Response (PR):  At  least a 30% decrease in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters.  
 Progressive Disease (PD):   At least a 20% increase in the sum of the diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).  In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.  (Note:  the appearance of one or more new lesions is also considered progressions).  
 Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD, taking as reference the smallest sum diameters while on study.  
 
13.4.2 Evaluation of Non -Target Lesions  
 
Complete Response (CR):   Dis appearance of all non -target lesions and normalization of 
tumor marker level.  All lymph nodes must be non- pathological in size (<10 mm short 
axis).  
 
Note:  If tumor markers are initially above the upper normal limit, they must normalize for 
a patient to be considered in complete clinical response.  
 Non-CR/Non -PD:  Persistence of one or more non- target lesion(s) and/or maintenance of 
tumor marker level above the normal limits.  
 Progressive Disease (PD):   Appearance of one or more new lesions and/or unequivocal 
progression of existing non- target lesions.  Unequivocal progression should not normally 
trump target lesion status.  It must be representative of overall disease status change, not a single lesion increase.     
 
Version 03/16/2020 – Amendment 13   Page 60 of 87  
Although a clear progression of “non- target” lesions only is exceptional, the opi[INVESTIGATOR_12999], and the progression status should be confirmed at a later time by [CONTACT_463] (or Principal Investigator).  
 
13.4.[ADDRESS_545057] response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started).  The patient's b est response 
assignment will depend on the achievement of both measurement and confirmation criteria  
 
For Patients with Measurable Disease (i.e., Target Disease)  
Target 
Lesions  Non-Target 
Lesions  New 
Lesions  Overall 
Response  Best Overall Response 
when Confirmation is 
Required*  
CR CR No CR >4 wks. Confirmation**  
CR Non-CR/Non -
PD No PR 
>4 wks. Confirmation** CR Not evaluated  No PR 
PR Non-CR/Non -
PD/not 
evaluated  No PR 
SD Non-CR/Non -
PD/not 
evaluated  No SD Documented at least once >4 wks. from baseline**  
PD Any Yes or 
No PD 
no prior SD, PR or CR  Any PD***  Yes or 
No PD 
Any Any Yes PD 
* See RECIST 1.1 manuscript for further details on what is evidence of a new lesion.  
** Only for non- randomized trials with response as primary endpoint.  
*** In exceptional circumstances, unequivocal progression in non -target lesions may be 
accepted as disease progression.  
Note:  Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease pro gression at that time should be reported as “symptomatic 
deterioration.”  Every effort should be made to document the objective progression even after 
discontinuation of treatment.  
   
 
Version 03/16/2020 – Amendment 13   Page 61 of 87                                       For Patients with Non -Measurable Disease (i.e., Non -Target Disease)  
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/non -PD* 
Not all evaluated  No not evaluated  
Unequivocal PD  Yes or No  PD 
Any Yes PD 
*  ‘Non -CR/non -PD’ is preferred over ‘stable disease’ for non -target disease since SD is 
increasingly used as an endpoint for assessment of efficacy in some trials so to assign this 
category when no lesions can be measured is not advised  
 
13.4.4 Duration of Response  
 
Duration of overall response:   The dura tion of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date 
that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).  
 The duration of overall CR is measured from the time measurement criteria are first met for CR until the first date that progressive disease is objectively documented.   
 Duration of stable disease:   Stable disease is measured from the start of the treatment 
until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements.  
  
14.[ADDRESS_545058] (DSMB) will be specifically convened for this trial to review toxicity data.  A DSMB will consist of no few er than [ADDRESS_545059]. Louis Children’s Hospi[INVESTIGATOR_307].  Like investigators, DSMB members are subject to the 
Washington U niversity School of Medicine policies regarding standards of conduct. Individuals invited 
to serve on the DSMB will disclose any potential conflicts of interest to the trial principal investigator 
[INVESTIGATOR_1238]/or appropriate university officials, in accordance with institution policies.  Potential conflicts that 
develop during a trial or a member’s tenure on a DSMB must also be disclosed.  
 Until such a time as the first secondary site enrolls its first patient, a semi- annual DSM report to be 
prepared by [CONTACT_1758] t eam will be submitted to the Quality Assurance and Safety Monitoring Committee 
(QASMC) semi -annually beginning six months after study activation at Washington University (if at least 
one patient has been enrolled) or one year after study activation (if no patients have been enrolled at the six-month mark).  
 The DSM report for the DSMB will be prepared by [CONTACT_430965], will be reviewed by [CONTACT_4318], and will be submitted to the QASM Committee.  The DSMB must meet at least every six months beginning six months after study activation at Washington University 
or six months after enrollment of the first patient at a secondary site, no more than one month prior to the due date of the DSM report to QASMC.  This report wi ll include:  
 
Version 03/16/2020 – Amendment 13   Page 62 of 87  
• HRPO protocol number, protocol title, Principal Investigator [CONTACT_2300], data coordinator name, 
regulatory coordinator name, and statistician  
• Date of initial HRPO approval, date of most recent consent HRPO approval/revision, date of 
HRPO expi[INVESTIGATOR_1516], date of most recent QA audit, study status, and phase of study  
• History of study including summary of substantive amendments; summary of accrual suspensions 
including start/stop dates and reason; and summary of protocol exceptions, error, or breach of confidentiality including start/stop dates and reason 
• Study- wide target accrual and study- wide actual accrual including numbers from participating sites  
• Protocol activation date at each participating site  
• Average rate of accrual observed in year 1, year 2, and subsequent years at each participating site  
• Expected accrual end date, accrual by [CONTACT_3725]  
• Objectives of protocol with supporting data and list the number of participants who have met each 
objective  
• Measures of efficacy  
• Early stoppi[INVESTIGATOR_430911]  
• Summary of toxicities at all participating sites  
• Abstract submissions/publications  
• Summary of any recent literature that may affect the safety or ethics of the study  
 
Further DSMB responsibilities are described in the DSMB charter.  
 
The study principal investigator [INVESTIGATOR_288871]. Once the principal investigator [INVESTIGATOR_430912], the AE will be reported to the HRPO and QASMC according to institutional guidelines.  
 Refer to the Washington University Quality Assurance and Data Safety Monitoring Committee Policies and Procedures for full details on the responsi bilities of the DSMC.  This is located on the QASMC 
website at https://siteman.wustl.edu/research/clinical -research -resources/protocol -office -prmcqasmc/  
 
14.[ADDRESS_545060] the safety and well- being of human subjects until the IRB can assess the monitor’s report.  The 
research monitor has the responsibility to promptly report his/her findings to the IRB or other designated official and to the US Army Medical Research and Materiel Command, Off ice of 
Research Protections, Human Research Protection Office.  
 In addition, the independent research monitor  is required to review all unanticipated problems 
involving risk to subjects or others, serious adverse events, and all subject deaths associated w ith 
 
Version 03/16/2020 – Amendment [ADDRESS_545061] also indicate whether he/she concurs with the details of the report provided by [CONTACT_458].  
  
15.0 AUDITING  
 
Since Washington University is the coordinating center, each site will be audited annually by [CONTACT_295805] (QASMC) unless the outside institution has an auditing mechanism in place and can provide a report. The outside sites will be asked to send copi[INVESTIGATOR_205143] , including source 
documentation.  The audit notification will be sent to the Washington University Research Patient 
Coordinator, who will obtain the audit materials from the participating institution.  
 Notification of an upcoming audit will be sent to the research team one month ahead of t he audit. Once 
accrual numbers are confirmed, and approximately [ADDRESS_545062] of the cases selected for review (up to 10 for each site) will be sent to the research team. However, if during the audit the need arises to review cases not  initially selected, the research team will be asked to provide the additional charts 
within two working days.  Additional details regarding the Auditing Policies and procedures can be found at https://siteman.wustl.edu/wp- content/uploads/2015/QASMC -Polici es-and-Procedures -03.31.2015.pdf  
  
16.0 STATISTICAL CONSIDERATIONS  
 
16.1 Study Objectives  
 
16.1.1 Primary Objective s 
 
1. To determine the clinical benefit  (CR+PR+SD> 6 months) of neratinib alone  in 
patients with metastatic HER2 - breast cancer that carry HER2 mutations (Part I)  
2. To examine the clinical benefit (CR+PR +SD>6 months ) of neratinib in combination 
with fulvestrant in patients with fulvestrant naïve metastatic HER2 -, ER+ breast 
cancer carrying activating HER2 mutations (Part II fulvestrant naïve ER+ cohort)  
3. To examine th e clinical benefit (CR+PR+SD >6 months)  of neratinib in combination 
with fulvestrant in patients with metastatic HER2 -, ER+ breast cancer carrying 
activating HER2 mutations previously treated with fulvestrant (Part II fulvestrant 
treated ER+ cohort)  
4. To dete rmine the clinical benefit rate of neratinib alone in patients with metastatic 
HER2 -, ER- breast cancer carrying activating HER2 mutations (Part II ER - cohort)  
 
16.1.[ADDRESS_545063] cancers by [CONTACT_430932]2 
mutations (activ ating vs unknown significance)  
 
Version 03/16/2020 – Amendment 13   Page 64 of 87 2. To assess the PFS and RR of neratinib in combination with fulvestrant in patients with 
fulvestrant naïve metastatic ER+ HER2 - breast cancer carrying activating HER2 
mutations  
3. To assess the PFS and response rate for neratinib in combination with fulvestrant in 
patients with metastatic HER2 -, ER+ breast cancer carrying activating HER2 
mutations previously treated wi th fulvestrant  
4. To correlate the presence of HER2 mutation with histology subtype (invasive lobular vs. invasive ductal cancer), tumor grade (grade 1- 2 vs 3), tumor staging at initial 
diagnosis (I vs. II or III vs. IV), disease free survival in HER2 - breast  cancer  
5. To assess the safety profile and tolerability of neratinib in combination with fulvestrant in patients with metastatic ER+, HER2 - breast cancer carrying activating 
HER2 mutations  
 
16.1.[ADDRESS_545064] 
cancer carrying HER2 mutations :  
 Patients with any somatic HER2 mutations identified are eligible for the study. Based on Simon’s 
Optimal 2 -stage design, our ultimate goal is to enroll a total of 29 patients with HER2 mutations. 
This will allow us 80% power at a 1- sided 0.[ADDRESS_545065] an anticipated 20% 
clinical benefit rate against the null hypothesis of 5%.  Ten patients will be enrolled in the first stage. Accrual will continue until [ADDRESS_545066] shown clinical benefit, a total of 19 patients (with or without known activating 
mutations, depending on the enrollment criterion in stage 1) will be enrolled in the 2nd stage.   In a 
multicenter study such as this, however, it is difficult for a trial to reach the planned sample exactly.  
The investigators would not turn away patients who have already been approached for participation just because the number of patients needed has been met.  Therefore, we adopted a f lexible Phase 
II design (Chen and Ng 1998) to allow the actual number at final stage to deviate slightly from what is planned.  That is, i f 4 or more cases with clinical benefit are observed out of 29- 34 patients, 
or 5 or more cases with clinical benefit are observed out of 35 or more patients, we would conclude that preliminary evidence for efficacy exists and that further investigation of the treatment is warranted.   
 As of Jan 17
th 2015, 10 evaluable patients with HER2 mutations, including 9 with activating 
mutations, were enrolled in the study.  Among these patients, 1 patient with activating mutation 
 
Version 03/16/2020 – Amendment 13   Page 65 of 87 derived clinical benefit with a partial response.  However, since majority of pat ients (15 of 16) 
found to have HER2 mutations in the study had ER+ breast cancer, we propose to add fulvestrant 
to neratinib in the ER+ population in the second part of the study to evaluate the overall response rate for this combination.  The first part o f the trial will close once the amendment (amendment 7) 
for the second part of the trial is approved.  As of Aug ust 25
th, 2015, amendment 7 has been  
approved by [CONTACT_430966];  therefore enrollment is only open to the second part trial 
since that date.  
 
Sample size justification for the second part of the trial with  neratinib alone in patients with 
metastatic ER - HER2 - breast cancer carrying HER2 mutations:  We will enroll 10 patients. This 
will provide us a reasonable precision to estimate the clinical benefit (CR+PR+SD >6 months) of 
neratinib alone  in patients with metastatic ER -/HER2 - breast cancer that carry HER2 mutations. If 
[ADDRESS_545067] 80% confidence that the true rate w ill be above 5%. Conversely, if the "true" response rate is above 20%, there will 
only 10% chance to observe none clinical benefit out of 10 patients.  
 
Sample size justification for the Part II fulvestrant naïve ER+ Cohort:  Based on the phase III trials 
PALOMA 3 (fulvestrant alone vs fulvestrant + palbo), the CBR for fulvestrant naïve endocrine resistant population is 40% and adding palbo increase CBR to 67%. W e propose a sample size of 
26 evaluable patients. Based on Simon’s  Minimax  design, this will allow us 80% power at a 1-
sided 0.[ADDRESS_545068] an anticipated 65% response  rate for fulvestrant plus 
neratinib combination therapy against the null hypothesis of 40%.  Specifically, [ADDRESS_545069] stage. If 6 or more clinical benefits  are observed out of the se 12 patients, 
additional 1 4 patients will be enrolled to the 2
nd-stage. If 15 or more cases with clinical benefits  
are observed out of 26 patients, we would conclude that prelimi nary evidence for efficacy exists 
and that further investigation of the treatment is warranted.  If the “true” response rate is 40%  or 
less, this design allows us 67% chance to stop the trial earlier.   
 
Sample size justification for the Part II fulvestrant treated ER+ Cohort : Patients enrolled in this 
cohort has had disease progression on prior fulvestrant, therefore we anticipate fulvestrant alone would be ineffective. Sinc e neratinib alone resulted in clinical benefit rate of 38.5% (5 of 13 
evaluable  patients  with metastatic ER+ breast cancer that carry activating HER2 mutations ) based 
on the preliminary efficacy data observed in the part I of this trial, we propose a sample size of 41  
evaluable patients. Based on Simon’s Minimax  design, this will all ow us 80% power at a 1- sided 
0.[ADDRESS_545070] an anticipated 55% clinical benefit rate for fulvestrant plus 
neratinib combination therapy against the null hypothesis of 35%. Specifically, [ADDRESS_545071] stage. If  9 or more clinical benefits are observed out of 21 patients, additional 
20 patients will be enrolled to the 2
nd-stage.  If 20 or more cases with clinical benefit are observed 
out of 41 patients, we would conclude that preliminary evidence for efficacy exi sts and that further 
investigation of the treatment is warranted.  If the “true” benefit rate is 35% or less, this design 
allows us 70% chance to stop the trial earlier.     
 
In total, 77 patients (10 ER -, 26 ER+ fulvestrant naïve, 41 ER+ fulvestrant treated) will be 
enrolled  in Part II of this study.  
 16.3 Data A nalysis  
 
Data analysis will be per formed for Parts I and II separately.  Only patients with tumors tested 
positive for HER2 mutations are eligible for study therapy but  the clinical and pathology data will 
 
Version 03/16/2020 – Amendment 13   Page 66 of 87 be collected for all screened patients.  Subset analysis will also be performed on patients with 
known activating mutations if needed. 
 
For patients with HER2 mutation, the number and percentage of responses to neratin ib alone (Part  
I, and Part II ER - cohort ) or neratinib in combination with fulvestrant (Part II, fulvestrant naïve 
and fulvestrant treated cohorts ) will be tabulated. The rate of overall clinical benefit (CR, PR, or 
SD > 6 months) and its 90% confidence interval (CI) will be calculated  in each cohort separately . 
The time to progression or death will be listed, and the progression- free survival (PFS) will be 
estimated using Kaplan- Meier product limit method  in each cohort .  For all the enrolled patients, 
the number and percentage of patients with HER2 mutation will be presented, and its 95% CI will also be calculated. The agreement for the occurrence of HER2 mutation in paired primary and metastatic sites will be described  using contingency tables and assess by [CONTACT_430967]. The 
association of the presence of HER2 mutation with histology subtype (invasive lobular vs invasive 
ductal cancer), tumor grade, tumor staging at initial diagnosis (I vs II or III vs IV), and disease-
free survival ( DFS) will be assessed using Fisher’s exact test, Mann -Whitney rank sum test, or 
log-rank test as appropriate.  
 
 
17.0 MULTICENTER REGULATORY REQUIREMENTS  
 Washington University requires that each participating site sends  its informed consent docum ent to be 
reviewed and approved by [CONTACT_430968] (or designee ) prior to 
IRB/IEC submission.    
 Each participating institution must have the following documents on file at Washington University prior 
to first subject enro llment:  
• Documentation of IRB approval  of the study in the form of a letter or other official document from 
the participating institution’s IRB.   This documentation must show which version of the protocol 
was approved by [CONTACT_1201]. 
• Documentation of IRB approval of an informed consent form . The c onsent must include a 
statement that data will be shared with Washington University, including the Quality Assurance 
and Safety Monitoring Committee (QASMC), the DSMC  (if applicable) , and the Washington 
University study team.  
• Documentation of FWA, signed FDA Form 1572, and signed and dated CVs of all participating 
investigators.  
• Documentation of training in protection of human subjects by [CONTACT_430969].  
• Protocol signature [CONTACT_144904] [CONTACT_144903].  
 The Principal Investigator [INVESTIGATOR_430913], 
amendments, reportable adverse events, etc.  There will be one current version of the protocol document 
at any  given time and each participating institution will utilize that document.  Protocol /consent  
modifications and IB updates will be forwarded electronically to the secondary sites within 2 weeks of 
obtaining Washington University IRB  approval with acknowledgement of receipt requested.  Secondary 
sites are to submit protocol/consent/IB  modifications to their local IRBs within [ADDRESS_545072] person on the W ashington 
University study team at the time of submission .  Upon the secondary sites obtaining local IRB approval, 
documentation of such shall be sent to the Washington University study team  within 2 weeks of receipt 
of approval.  
 
 
Version 03/16/2020 – Amendment 13   Page 67 of 87 Documentation of participating sites’ IRB approval of annual continuing reviews, protocol amendments 
or revisions, all SAE reports, and all protocol violations/deviations/exceptions must be kept on file at Washington University.  
 The investigator or a designee from each institution must participate in a regular conference call to update and inform regarding the progress of the trial.  
  
 
Version 03/16/2020 – Amendment 13   Page 68 of 87 18.0 REFERENCES  
 
1. Ma CX, Luo J, Ellis MJ: Molecular profiling of triple negative breast cancer. Breast di sease 
2010, 32(1):73- 84. 
2. Mouridsen H, Gershanovich M, Sun Y, Perez -Carrion R, Boni C, Monnier A, Apffelstaedt J, 
Smith R, Sleeboom HP, Jaenicke F  et al : Phase III study of letrozole versus tamoxifen as 
first- line therapy of advanced breast cancer in postmenopausal women: analysis of survival 
and update of efficacy from the International Letrozole Breast Cancer Group . Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 2003, 21(11):2101 -2109. 
3. Kiely BE, Soon YY, Tattersall MH, Stockler MR: How long have I got? Estimating typi[INVESTIGATOR_2855], 
best-case, and worst -case scenarios for patients starting first -line chemotherapy for 
metastatic breast cancer: a systematic review of recent randomized trials. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 2011, 29(4):456- 463. 
4. Yarden Y: The EGFR family and its ligands in human cancer. signalling mechanisms and 
therapeutic opportunities . Eur J Cancer 2001, [ADDRESS_545073] 4 :S3-8. 
5. Harari PM, Allen GW, Bonner JA: Biology of interactions: antiepi[INVESTIGATOR_430914]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007, 25(26):4057- 4065. 
6. Slamon DJ, Leyland- Jones B, Shak S, Fuchs H, Pat on V, Bajamonde A, Fleming T, Eiermann 
W, Wolter J, Pegram M et al: Use of chemotherapy plus a monoclonal antibody against 
HER2 for metastatic breast cancer that overexpresses HER2 . N Engl J Med 2001, 
344(11):783 -792. 
7. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, Jr., Martino S, Mamounas EP, Kaufman PA, Wolmark N: Four -year follow -up of trastuzumab plus adjuvant 
chemotherapy for operable human epi[INVESTIGATOR_3506] [ADDRESS_545074] 
cancer: joint analysis of data from NCCTG N9831 and NSABP B -31. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 2011, 29(25):3366-
3373. 
8. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, Tan- Chiu E, Martino 
S, Paik S, Kaufman PA  et al: Trastuzumab plus adjuvant chemotherapy for operable HER2 -
positive breast cancer. N Engl J Med 2005, 353(16):1673- 1684. 
9. Smith I, Procter M, Gelber RD, Guillaume Sb, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, M ariani G, Baselga J  et al : 2-year follow -up of trastuzumab after adjuvant chemotherapy 
in HER2 -positive breast cancer: a randomised controlled trial . The Lancet , 369(9555):29- 36. 
10. Robert N, Leyland- Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre 
R, Cobleigh M  et al : Randomized Phase III Study of Trastuzumab, Paclitaxel, and 
Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER -2Â–
Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology 2006, 24(18) :2786-
2792. 
11. Abramson V, Arteaga CL: New Strategies in HER2 -Overexpressing Breast Cancer: Many 
Combinations of Targeted Drugs Available . Clinical Cancer Research , 17(5):[ADDRESS_545075], Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M  et al : Efficacy and safety of trastuzumab as a single 
agent in first- line treatment of HER2 -overexpressing metastatic breast cancer. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 2002, 
20(3):719 -726. 
 
Version 03/16/2020 – Amendment [ADDRESS_545076], Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany 
R, Senz J  et al : Mutational evolution in a lobular breast tumour profiled at single nucleotide 
resolution . Nature 2009, 461(7265):809- 813. 
14. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH  
et al: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast 
carcinomas . Clinical cancer research : an official journal of the Am erican Association for 
Cancer Research 2006, 12(1):57 -61. 
15. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J  et al : Diverse somatic mutation patterns and pathway alterations in human 
cancers. Nature 2010, 466 (7308):869- 873. 
16. Rabindran SK: Antitumor activity of HER -2 inhibitors . Cancer Letters 2005, 227(1):9 -23. 
17. Tsou H -R, Overbeek- Klumpers EG, Hallett WA, Reich MF, Floyd MB, Johnson BD, Michalak 
RS, Nilakantan R, Discafani C, Golas J  et al : Optimization of 6,7- Disubstituted -4-
(arylamino)quinoline -3-carbonitriles as Orally Active, Irreversible Inhibitors of Human 
Epi[INVESTIGATOR_14907]- 2 Kinase Activity . Journal of Medicinal Chemistry 2005, 
48(4):[ADDRESS_545077] EC, Baxter M, Floyd MB, Golas J, Hallett WA, Johnson BD, Nilakantan R, Overbeek E  et al : Antitumor activity of HKI -272, an orally active, 
irreversible inhibitor of the HER -2 tyrosine kinase . Cancer research 2004, 64(11):3958-
3965. 
19. Burstein HJ,  Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, 
Schwartz G  et al : Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in 
patients with advanced ErbB2 -positive breast cancer. Journal of clinical oncology : official  
journal of the American Society of Clinical Oncology 2010, 28(8):1301 -1307. 
20. Howell A, Pi[INVESTIGATOR_229226] J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, 
Robertson JF: Fulvestrant versus anastrozole for the treatment of advanced breast carcinom a: a prospectively planned combined survival analysis of two multicenter trials . 
Cancer 2005, 104(2):236 -239. 
21. Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S  et al : Fulvestrant versus anastro zole for the treatment of advanced 
breast carcinoma in postmenopausal women: a prospective combined analysis of two 
multicenter trials . Cancer 2003, 98(2):229- 238. 
22. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, 
Robertson JF  et al : Double -blind, randomized placebo controlled trial of fulvestrant 
compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor- positive, advanced breast cancer: results 
from EFECT. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 2008, 26(10):1664- 1670. 
23. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR  et al : Results of the CONFIRM phase III trial 
comparing fulvestrant [ADDRESS_545078] cancer. J Clin Oncol 2010, 28(30):4594- 4600. 
24. Di Leo A, Jerusalem G, Petruzelka L , Torres R, Bondarenko IN, Khasanov R, Verhoeven D, 
Pedrini JL, Smirnova I, Lichinitser MR  et al : Results of the CONFIRM phase III trial 
comparing fulvestrant [ADDRESS_545079] cancer. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 2010, 28(30):[ADDRESS_545080], Barry WT, Chew HK, Tolaney SM, Lake DE, Ma C, Blackwell 
KL, Winer EP, Hudis CA: Endocrine Therapy With or Without Inhibition of Epi[INVESTIGATOR_430915] 03/16/2020 – Amendment 13   Page 70 of 87 Growth Factor Receptor and Human Epi[INVESTIGATOR_14907] 2: A 
Randomized, Double -Blind, Placebo -Controlled Phase III Trial of Fulvestrant With or 
Without Lapatinib for Postmenopausal Women With Hormone  Receptor- Positive 
Advanced Breast Cancer- CALGB [ZIP_CODE] (Alliance) . J Clin Oncol 2014, 32(35):3959- 3966. 
26. Robertson JF, Steger GG, Neven P, Barni S, Gieseking F, Nole F, Pritchard KI, O'Malley FP, Simon SD, Kaufman B  et al: Activity of fulvestrant in HER2 -overexpressing advanced 
breast cancer. Ann Oncol 2010, 21(6):1246- 1253. 
27. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A: p185HER2 
monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast 
tumor cells to tu mor necrosis factor. Mol Cell Biol 1989, 9 (3):1165 -1172. 
28. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J: Recombinant humanized anti -HER2 
antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpr essing human breast cancer xenografts. Cancer research 1998, 
58(13):2825 -2831. 
29. Pegram MD, Baly D, Wirth C, Gilkerson E, Slamon DJ, Sliwkowski MX: Antibody dependent 
cell-mediated cytotoxicity in breast cancer patients in Phase III clinical trials of a 
humanized anti -HER2 antibody [abstract] . Proc Am Assoc Cancer Res 1997, 38:602. 
30. Hotaling TE, Reitz B, Wolfgang- Kimball D, K B, Fox JA: The humanized anti -HER2 
antibody rhuMAb HER2 mediates antibody dependent cell -mediated cytotoxicity via FcgR 
III [abstract].  Proc Annu Meet Am Assoc Cancer Res 1996, 37:471. 
31. Hudis CA: Trastuzumab â€” Mechanism of Action and Use in Clinical Practice . New 
England Journal of Medicine 2007, 357 (1):[ADDRESS_545081], Fehre nbacher L, Slamon DJ, 
Murphy M, Novotny WF, Burchmore M  et al : Efficacy and safety of trastuzumab as a single 
agent in first- line treatment of HER2 -overexpressing metastatic breast cancer. Journal of 
Clinical Oncology 2002, 20(3):719 -726. 
33. Baselga J, Carbonell X, CastaÃ±eda -Soto N -J, Clemens M, Green M, Harvey V, Morales S, 
Barton C, Ghahramani P: Phase II Study of Efficacy, Safety, and Pharmacokinetics of 
Trastuzumab Monotherapy Administered on a 3 -Weekly Schedule . Journal of Clinical 
Oncol ogy 2005, 23(10):2162- 2171. 
34. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G  et al : Multinational Study of the Efficacy and Safety of Humanized 
Anti -HER2 Monoclonal Antibody in Women Who Have HER2 -Overexpressing Metastatic 
Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease . Journal of 
Clinical Oncology 1999, 17(9):2639. 
35. Pi[INVESTIGATOR_94899] -Gebhart MJ, Procter M, Leyland -Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, 
Baselga J, Bell R, Jackisch C  et al : Trastuzumab after adjuvant chemotherapy in HER2 -
positive breast cancer. N Engl J Med 2005, 353(16):1659- 1672. 
36. Nahta R, Esteva FJ: Herceptin: mechanisms of action and resistance. Cancer Lett 2006, 
232(2):123 -138. 
37. O'Donovan N, By[CONTACT_180278], O'Connor AE, McGee S, Gallagher WM, Crown J: Synergistic 
interaction between trastuzumab and EGFR/HER -[ADDRESS_545082] cancer cells. Investigational new drugs 2011, 29(5):752 -759. 
38. Baselga J, Cort es J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pi[INVESTIGATOR_118487] T, 
Knott A  et al : Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N 
Engl J Med 2012, 366(2):109- 119. 
39. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, 
Vukelja S, Bischoff J  et al : Randomized Study of Lapatinib Alone or in Combination With 
 
Version 03/16/2020 – Amendment [ADDRESS_545083] 
Cancer. Journal of Clinical Oncology 2010, 28(7):1124- 1130. 
40. Valachis A, Nearchou A, Polyzos NP, Lind P: Cardiac toxicity in breast cancer patients 
treated with dual HER2 blockade . International journal of cancer Journal international du 
cancer 2013, 133(9):2245- 2252. 
41. Swaby R, Blackwell K, Jiang Z, Sun Y, Dieras V, Zaman K, Zacharchuk C, Powell C, Abbas R, Thakuria M: Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study . Journal of Clinical Oncology 2009, 27 (15).  
42. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER -2/neu oncogene . Science 
1987, 235(4785):177- 182. 
43. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hart wick 
RW, Hanna W, Lickley L  et al : neu/erbB -[ADDRESS_545084] Cancer Study Group . Journal 
of clinical oncology : official journal of the American Society of Clinical Oncology 1998, 
16(4):1340 -1349. 
44. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c-
erbB -[ADDRESS_545085] cancer, alone and in combination with other 
prognostic markers. Journal of clinical onco logy : official journal of the American Society of 
Clinical Oncology 1998, 16(2):462 -469. 
45. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH  
et al: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast 
carcinomas . Clin Cancer Res 2006, 12(1):[ADDRESS_545086], Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany 
R, Senz J  et al : Mutational evolution in a lobular breast tumour profiled at single nucleotide 
resolution . Nature 2009, 461(7265):809- 813. 
47. Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G  et 
al: The clonal and mutational evolution spectrum of primary triple -negative breast cancers. 
Nature 2012:doi: 10.1038/nature10933. 
48. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, Zainal SN, al. E: The landscape of cancer genes and mutational processes in breast cancer. Nature 2012:doi:10.1038/nature11017. 
49. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW , Van Tine BA, Hoog J, Goiffon RJ, 
Goldstein TC  et al : Whole Genome Sequencing to Characterise Breast Cancer Response to 
Aromatase Inhibition . Nature 2012:doi: 10.1038/nature11143. 
50. Cancer Genome Atlas Network T: Comprehensive molecular portraits of human breast tumors.  Nature 2012:In Press.  
51. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S  et al : Activating HER2 mutations in HER2 gene amplification negative breast 
cancer. Cancer Discov 2013, 3(2):224 -237. 
52. Moy B, Kirkpatrick P, Kar S, Goss P: Lapatinib. Nat Rev Drug Discov 2007, 6(6):431- 432. 
53. Kwak EL, Sordella R, Bell DW, Godin- Heymann N, Okimoto RA, Brannigan BW, Harris PL, 
Driscoll DR, Fidias P, Lynch TJ  et al : Irreversible inhibitors of the E GF receptor may 
circumvent acquired resistance to gefitinib . Proc Natl Acad Sci U S A 2005, 102(21):7665-
7670. 
54. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS: The role of 
apoptosis in creating and maintaining luminal space within normal and oncogene -
expressing mammary acini . Cell 2002, 111(1):29- 40. 
 
Version 03/16/2020 – Amendment 13   Page 72 of 87 55. Debnath J, Muthuswamy SK, Brugge JS: Morphogenesis and oncogenesis of MCF -10A 
mammary epi[INVESTIGATOR_430916] -dimensional basement membrane cultures. 
Methods 2003, 30(3):2 56-268. 
56. Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, 
Ambrogio L  et al : Functional analysis of receptor tyrosine kinase mutations in lung cancer 
identifies oncogenic extracellular domain mutations of ERBB2 . Proc N atl Acad Sci U S A 
2012, 109(36):[ZIP_CODE]- [ZIP_CODE]. 
57. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S  et al : Activating HER2 Mutations in HER2 Gene Amplification Negative Breast 
Cancer. Cancer discovery 2013, 3(2 ):224- 237. 
58. de Martino M, Zhuang D, Klatte T, Rieken M, Rouprêt M, Xylinas E, Clozel T, Krzywinski M, Elemento O, Shariat SF: Impact of ERBB2 mutations on in vitro sensitivity of bladder 
cancer to lapatinib . Cancer biology & therapy 2014, 15(9):1239- 1247. 
59. Trowe T, Boukouvala S, Calkins K, Cutler RE, Jr., Fong R, Funke R, Gendreau SB, Kim YD, Miller N, Woolfrey JR  et al : EXEL- 7647 inhibits mutant forms of ErbB2 associated with 
lapatinib resistance and neoplastic transformation . Clinical cancer research : an official 
journal of the American Association for Cancer Research 2008, 14(8):2465- 2475. 
60. Kancha RK, von Bubnoff N, Bartosch N, Peschel C, Engh RA, Duyster J: Differential sensitivity of ERBB2 kinase domain mutations towards  lapatinib . PloS one 2011, 
6(10):e26760. 
61. Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL: Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to d ual inhibition of EGFR and HER2 . 
Clinical cancer research : an official journal of the American Association for Cancer Research 
2013, 19(19):5390- 5401. 
62. Sun Z, Shi Y, Shen Y, Cao L, Zhang W, Guan X: Analysis of different HER ‐[ADDRESS_545087] cancer progression and drug resistance . Journal of Cellular and Molecular Medicine 
2015, 19(12):2691- 2701. 
63. Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, Gallagher KT, Woldu E, Carter HL, 
Truesdale AT, Shewchuk L  et al : Impact of common epi[INVESTIGATOR_430917]2 variants on receptor activity and inhibition by [CONTACT_430930] . Cancer research 2008, 
68(2):571 -579. 
64. Hu Z, Hu Y, Liu X, Xi R, Zhang A, Liu D, Xie Q, Chen L: Tumor driven by [CONTACT_83141] -of-function 
HER2 H878Y mutant is highly sensitive to HER2 inhibitor . Oncotarget 2015, 6(31):[ZIP_CODE]-
[ZIP_CODE]. 
65. Fan YX, Wong L, Ding J, Spi[INVESTIGATOR_430918], Johnson RC, Johnson GR: Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism . J Biol Chem 2008, 
283(3):1588 -1596. 
66. Minami Y, S himamura T, Shah K, LaFramboise T, Glatt KA, Liniker E, Borgman CL, 
Haringsma HJ, Feng W, Weir BA  et al : The major lung cancer- derived mutants of ERBB2 
are oncogenic and are associated with sensitivity to the irreversible EGFR//ERBB2 
inhibitor HKI -272. Onc ogene 2007, 26(34):5023- 5027. 
67. Wang SE, Narasanna A, Perez- Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, 
Muthuswamy SK, Arteaga CL: HER2 kinase domain mutation results in constitutive 
phosphorylation and activation of HER2 and EGFR and resis tance to EGFR tyrosine 
kinase inhibitors . Cancer Cell 2006, 10(1):25 -38. 
68. Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer EP, Naughton MJ, Goetz 
MP, Russell C  et al : Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 
 
Version 03/16/2020 – Amendment [ADDRESS_545088] Cancer. Clinical cancer research : an 
official journal of the American Association for Cancer Research 2017. 
69. De Mattos -Arruda L, Caldas C: Cell -free circulating tumour DNA as a liquid biopsy in 
breast cancer. Mol  Oncol 2016, 10(3):464- 474. 
70. Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, Collisson EA, Divers SG, 
Hoon DS, Kopetz ES  et al : Analytical and Clinical Validation of a Digital Sequencing Panel 
for Quantitative, Highly Accurate Evaluation of Cell- Free Circulating Tumor DNA . PloS 
one 2015, 10(10):e0140712. 
 We would like to thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes- Jewish Hospi[INVESTIGATOR_195577]. Louis, Missouri, for the use of the Clinical Trials Core 
which provided protocol development, study coordination, and re gulatory coordination services . The 
Siteman Cancer Center is supported in part by [CONTACT_195605] #P30 CA91842.
 
Version 03/16/2020 – Amendment 13   Page 74 of 87  
APPENDIX A:  ECOG PERFORMANCE STATUS SCALE  
 
 
Grade  
  
Description  
0 Normal activity.  Fully active, able to carry on all pre -disease 
performance without restriction.  
1 Symptoms, but ambulatory.  Restricted in physically strenuous 
activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work).  
2 In bed <50% of the time.  Ambulatory and capable of all self -care, but 
unable to carry out any work activities.  Up and about more than 50% of waking hours.  
3  
In bed >50% of the time.  Capable of only limited self -care, confined 
to bed or chair more than 50% of waking hours.  
 
4 100% bedridden.  Completely disabled.  Cannot carry on any self -care.  
Totally confined to bed or chair.  
5  
Dead.  
 
 
Version 03/16/2020 – Amendment 13   Page 75 of 87 APPENDIX B : PATIENT’S MEDICATION DIARY  
Today’s Date:       Agent:  Neratinib  Study ID#:      
 
Cycle:         Patient Name:        
1. Complete one form for each month.  Take _____mg ( ___tablets ) of neratinib daily with food every 
morning.  
2. Record the date, the number of capsules taken, and when you took them.  
3. If you forg et to take your neratinib dose within [ADDRESS_545089] the time if you should vomit.  
5. Please return the forms to y our physician or your study coordinator when you go to your next 
appointment.  Please bring your unused study medications and/or empty bottles with you to each clinic visit so that a pi[INVESTIGATOR_288878].  
6. Avoid St. John’s wort, grapefruit, grapefruit jui ce, grapefruit hybrids, and star  fruit from 7 days before you 
start taking neratinib and throughout the entire study.   
Day Date  What time was 
dose taken?  # of tablets 
taken  # of loose 
stools  Antidiarrheals 
taken? y/n  Comments  
1       
2       
3       
4       
5       
6       
7       
8       
9       
10       
11       
12       
13       
14       
15       
16       
17       
18       
19       
20       
21       
22       
23       
24       
25       
26       
27       
28       
 
   
 
Version 03/16/2020 – Amendment 13   Page 76 of 87 APPENDIX C : PATIENT INSTRUCTIONS FOR THE MANAGEMENT OF DIARRHEA  
 
Please review these instructions with your study doctor/team.  Once all of your questions are 
answered, sign at the bottom and make sure you are given a copy of these instructions to take 
home.  
 
Diarrhea is the most common side effect you may have while participating in this study.  Diarrhea usually 
starts within a few hours to a few days of the first dose of study drug.  In order to reduce or even prevent 
diarrhea as far as possible, you will be supp lied with an anti -diarrheal medicine called loperamide to take 
at the start of the study. Primary prophylactic use of antidiarrheal medication is mandatory for all 
enrolled subjects.  Loperamide will be dispensed directly by [CONTACT_6814]/team on day [ADDRESS_545090] dose of neratinib as directed 
by [CONTACT_6814]/team.   
 Your study doctor/team will call you [ADDRESS_545091] an easy to follow flow -chart  to help you each day in the management of diarrhea if it 
is present.  
 If you are having new -onset diarrhea, persistent diarrhea or diarrhea with increase of 7 or more stools per 
day over usual, call your study doctor/team at 314 -362-8903 to let them know so they can work with you 
to control the diarrhea.  If you are dizzy or weak because of diarrhea, go to the study doctor’s office or go 
to the hospi[INVESTIGATOR_50716].  
 
Please record the number of stools and any anti -diarrheal treatment during the first two c ycles along with 
the daily dose of study medication in your diary  and return the completed diary at the next scheduled visit.  
 
 
Information to provide when talking to your doctor  
When talking to the study doctor/team I will provide as much of the informati on below as possible, in 
order to help my study doctor/team to assess my diarrhea and decide on the best treatment:  
• Number of stools per day as compared to my normal bowel habits  
• Presence of diarrhea during the night  
• Presence of fever, dizziness, abdominal  pain/crampi[INVESTIGATOR_007], or weakness  
• What the stool looks like, that is, watery stools, blood, or mucus   
• When I took my last study drug 
• Any other information that could explain my diarrhea (food, recent travel, contact [CONTACT_429158]).  
  
 
Version 03/16/2020 – Amendment 13   Page 77 of 87  
 
Medications to treat diarrhea  
My study doctor/team will provide me with loperamide on day [ADDRESS_545092] dose of neratinib.  I need to take the medications as directed by [CONTACT_60852]/team.  
 Loperamide:  
• I will take 2 tablets/capsules (4 mg) with the first dose of neratinib  
• After the first dose, I will take 4 mg (2 tablets/ capsules) three times daily for the first 14 
days(not to exceed a total of 8 tablets/day; if I get constipated, I should contact [CONTACT_430970]/team who will instruct me on how often and how much loperamide to take but I should 
not stop taking loperamide).  
• After the first 14 days, I will take 2 tablet s (4 mg) two times per day  until the end of the second  
cycle of therapy regardless of whether I have diarrhea or not.  If I get constipated, I should 
contact [CONTACT_60852]/team who will instruct me on how often and how much loperamide to take but I should not stop taking loperamide). 
• If I continue to have diarrhea while taking loperamide, I should contact [CONTACT_60852]/team for additional anti -diarrheal medication.  
• If I have diarrhea with increase of up to 6 stools per day over usual any time after completing the second  cycle of therapy and I am not taking any anti -diarrheal medication, I will take 4mg (2 
tablets/capsules) as needed (not to exceed 8 tablets capsules or 16 mg per day)  
• □ Other medication (Study doctor/team to write in name [CONTACT_429161]):  
________________________________________________________ 
 ______________________________________________________________________    
______________________________________________________________________    In case of more severe diarrhea and any diarrhea associated with fever, pain, infection, or dehydration, I may receive IV fluids, antibiotics and/or other medications.  
 
Changes to my diet to treat diarrhea  
If I have diarrhea, I will:  
• Stop all lactose -containing products (milk, yogurt, cheese, etc)  
• Drink 8 to 10 large glasses of cle ar liquids per day 
• Eat frequent small meals 
• Eat low fat foods such as the BRAT diet that includes b ananas, r ice, applesauce, and/or t oast:  
- The BRAT diet is a bland diet that is low in fat and fiber and will not irritate the stomach;  
- Bananas are high in potassium and can cause constipation which can help alleviate the diarrhea  
- Other similar foods are crackers, cooked cereals and pasta  
- This diet is not complete in nutrients and should only be taken for a short period of time and only upon the doctor’s advi ce 
 
My study doctor/team may have other suggestions for me. (Study doctor/team to write in any suggestions). ________________________________________________________  
 
 
Version 03/16/2020 – Amendment 13   Page 78 of 87  
 
 
 
 
 
 
 
 
 
 
Study Medication adjustments  
If I am experiencing loose stools or diarrhea and cannot reach my study doctor/team immediately, I will 
start taking anti -diarrheal medication per the instructions above until further advice is given by [CONTACT_430970]/team. If I have more than 4 -6 stools per day compared to normal despi[INVESTIGATOR_430919] -diarrheal 
medication for 24 hours, I will stop taking the study medication and wait for further instructions from my study doctor/team.  My signature [CONTACT_430971] I have reviewed this information and have received the following medications:  
□ Neratinib  Tablets   
□ Loperamide  
 
 
 ________________________________________________________________ Study participant name           [CONTACT_430972]  
    ________________________________________________________________ Investigator delegate name          [CONTACT_430973] 
    ________________________________________________________________ 
Investigator name                                  [CONTACT_430974] 03/16/2020 – Amendment [ADDRESS_545093] you already been taking loperamide over the previous 24 hours?  Do you have diarrhea?  
Take [ADDRESS_545094] been 12 
hours without a loose stool (maximum of 8 
tabs/24 hours)  
 
Call your doctor right away for further 
advice and keep taking loperamide.  Your 
doctor may recommend additional anti -
diarrhea medicine.  
Nothing more needs to be 
done at this time. Make 
sure you keep drinking 
plenty of fluids each day. Do you continue to have diarrhea despi[INVESTIGATOR_430920]?  
 
 
While waiting for your doctor’s advice:                                           
-Drink [ADDRESS_545095] (BRAT diet)                                                                      
-Stop all lactose -containing products  
 
 NO 
 Do you continue to have diarrhea despi[INVESTIGATOR_430921]?  
 
 
Version 03/16/2020 – Amendment 13   Page 80 of 87 
   
Site #/Description  
Modality Image 
# Dimen- 
sion cm  
Modality Image 
# Dimen- 
sion cm  
Modality Image 
# Dimen- 
sion cm  
Modality Image 
# Dimen- 
sion cm 
#[ADDRESS_545096] CT   CT   CT   CT   
#[ADDRESS_545097] CT   CT   CT   CT   
#[ADDRESS_545098]   
 0.0  0.0  0.0  0.0 
 
 
Site #/Description  
Modality Image 
# F/U 
Status  
Modality Image 
# F/U 
Status  
Modality Image 
# F/U 
Status  
Modality Image 
# F/U 
Status 
#[ADDRESS_545099] CT   CT   CT   CT   
#[ADDRESS_545100] CT   CT   CT   CT   
#[ADDRESS_545101] CT   CT   CT   CT   
#[ADDRESS_545102] CT   CT   CT   CT   
 
 
Site #/Description  
Modality Image 
# Dimen- 
sion cm  
Modality Image 
# Dimen- 
sion cm  
Modality Image 
# Dimen- 
sion cm  
Modality Image 
# Dimen- 
sion cm 
#[ADDRESS_545103] CT   CT   CT   CT   
#[ADDRESS_545104] CT   CT   CT   CT   
#[ADDRESS_545105]   
 APPENDIX D : RECIST 1.[ADDRESS_545106] the following: * Description of Target, Non-Target, or New  Lesions * Maximum of 5 Target lesions Version Date  10/30/2012 
 * Dimensional measurements of Lymph Nodes (LNs) are shor test axis and >1.5 cm * All other lesions are longest axis. 
* Follow Up  Status of Non-Target Lesions: Increase/Decrease/Stable/Resolved 
Date of Evalua tion 
Target Lesions Baseline 
 
 
 
  
 
 
 
 
 
Sum of Longest Dimensions 
Non-Target Lesions 
  
  
 
  
 
 
 
 
  
 
New Lesions 
   
 
  
 
  
 
Commen ts 
 
Initials/Date of Form Prep/Data Entr y SignatureDate 
Official IRAC Document - Do Not Mod ify - IRAC Staff Use Only 
 
Version 03/16/2020 – Amendment 13   Page 81 of 87 
  APPENDIX E: Definitions  
 
Adverse Events (AEs)  
 
Definition: any untoward medical occurrence associated with the use of a drug in 
humans, whether or not considered dr ug-related.  
 
Grading:  the descriptions and grading scales found in the revised NCI Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.03 will be utilized 
for all toxicity reporting.  A copy of the CTCAE version 4.03  can be downloaded 
from the  CTEP website.  
 
Attribution (relatedness), Expectedness, and Seriousness:  the definitions for the 
terms listed that should be used are those provided by [CONTACT_1762]’ Office for Human Research Protections (OHRP).  A copy of this guidance can be found on OHRP’s website:  
http://www.hhs.gov/ohrp/policy/advevntguid.html
 
 
Suspected Adverse Reaction (SAR)  
 
Definition: any adverse event for which there is a reasonable possibility that the 
drug caused the adverse event.  “Reasonable possibility” means there is evidence to suggest a causal relationship between the drug and the adverse event.  “Suspected adverse reaction” implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug  
 
Serious Adverse Event (SAE) or Serious Suspected Adverse Reaction  
 
As defined in 21 CFR 312.32 
 
Definition:  an adverse event or suspected adverse reaction is considered “serious” 
if, in the view of the investigator, it results in any of the follow ing outcomes:  
o Death  
o A life -threatening adverse event  
o Inpatient hospi[INVESTIGATOR_1081]  
o A persistent or significant incapacity or substantial disruption of the ability 
to conduct normal life functions  
o A congenital anomaly/birth defect  
o Any other important medical event that does not fit the criteria above but, based upon appropriate medical judgment, may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed above  
 
Unexpected Adverse Experience  
 
 
Version 03/16/2020 – Amendment 13   Page 82 of 87 
  Definition: any adverse drug experience, the specificity or severity of which is not 
consistent with the current investigator brochure (or risk information, if an IB is not 
required or available).  
 Events that are both ser ious AND unexpected where there is a reasonable 
possibility of relationship to study drug must be reported to the FDA.  
 
Life-Threatening Adverse Event / Life Threatening Suspected Adverse Reaction   
 
Definition : any adverse drug event or suspected adverse reaction is considered 
“life-threatening” if, in the view of the investigator, its occurrence places the 
patient at immediate risk of death. It does not include an adverse event or suspected adverse reaction that, had it occurred in a more severe form, mig ht have 
caused death.  
 
Unanticipated Problems  
 
Definition:  
 
• unexpected (in terms of nature, severity, or frequency based on the adverse 
reaction table (Table 63) in the most current Investigator Brochure ) given (a) 
the research procedures that are described in the protocol -related documents, 
such as the IRB -approved research protocol and informed consent document; 
and (b) the characteristics of the subject population being studied;  
• related or possibly related to participation in the research (in this guidance document, possibly related means there is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459]); and  
• suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.  
 
Noncompliance  
 
Definition: failure to follow any applicable regulation or institutional policies that govern human subjects research or fai lure to follow the determinations of the 
IRB.   Noncompliance may occur due to lack of knowledge or due to deliberate 
choice to ignore regulations, institutional policies, or determinations of the IRB. 
 
Serious Noncompliance  
 
Definition: noncompliance that materially increases risks, that results in substantial 
harm to subjects or others, or that materially compromises the rights or welfare of participants.  
 
Protocol Exceptions  
 
Version 03/16/2020 – Amendment 13   Page 83 of 87 
   
Definition: A planned deviation from the approved protocol that are under the 
research team’s control. Exceptions apply only to a single participant or a singular 
situation.  
 
Local IRB pre -approval of all protocol exceptions must be obtained prior to the 
event.  For secondary sites, the Washington University PI [INVESTIGATOR_430922], but it must also be submitted to the local IRB with documentation of approval forwarded to Washington University.  Washington University IRB  
approval is not required for protocol exceptions occurring at secondary sites. 
 
  
 
Version 03/16/2020 – Amendment 13   Page 84 of 87 
  APPENDIX F: Reporting Timelines  
Expedited Reporting Timelines  
Event  HRPO  QASMC  FDA  IBC 
(Not Applicable)  Puma Biotechnology, 
Inc. 
Serious AND 
unexpected suspected 
adverse reaction    Report no later than 15 
calendar days after it is 
determined that the 
information qualifies for 
reporting   Report within fifteen (15) 
days 
Unexpected fatal or 
life-threatening 
suspected adverse 
reaction    Report no later than 7 
calendar days after initial receipt of the information   Report within seven (7) 
days  
Unanticipated 
problem involving risk 
to participants or 
others  Report within 10 working days.  
If the event results in the death of a participant enrolled at 
WU/BJH/SLCH, report within 
1 working day.  Report via email after 
IRB acknowledgment     
Major devi ation  Report within 10 working days.  
If the event results in the death 
of a participant enrolled at 
WU/BJH/SLCH, report within 
[ADDRESS_545107] in the protocol 
or IB    Report no later than 15 
calendar days after it is 
determined that the 
information qualifies for 
reporting    
Complaints  If the complaint reveals an 
unanticipated problem involving risks to participants 
or others OR noncompliance,     
 
Version 03/16/2020 – Amendment 13   Page 85 of 87 
  Expedited Reporting Timelines  
Event  HRPO  QASMC  FDA  IBC 
(Not Applicable)  Puma Biotechnology, 
Inc. 
report within 10 working days.  
If the event results in the death 
of a participant enrolled at 
WU/BJH/SLCH, report within 
[ADDRESS_545108] current 
toxicity table from the 
DSM report is provided 
to the FDA with the 
IND’s annual report.  Report within thirty (30) days 
 (i.e., unrelated to study 
drugs or listed/expected 
event)  
Minor deviation  Report summary information at the time of 
continuing review.     
Complaints  If the complaint reveals an unanticipated problem 
involving risks to participants or ot hers OR 
noncompliance, report within 10 working days.  If 
the event results in the death of a participant 
enrolled at WU/BJH/SLCH, report within 1 
working day.  Otherwise, report at the time of 
continuing review.     
Incarceration  If withdrawing the participant poses a safety 
issue, report within 10 working days.   
    
 
Version 03/16/2020 – Amendment 13   Page 86 of 87 
  Routine Reporting Timelines  
If withdrawing the participant does not represent a 
safety issue and the patient will be withdrawn, 
report at continuing review.  
 
Expedited Reporting Timelines for S econdary Sites  
Event  WU (Coordinating Center)  Local IRB  FDA  Puma Biotechnology, Inc.  
Serious AND unexpected 
suspected adverse reaction  Report no later than 11 calendar days 
after it is determined that the information 
qualifies for reporting.  Report all applicable 
events to local IRB 
according to local 
institutional guidelines. The research team at 
Washington University is 
responsible for reporting all 
applicable events to the 
FDA as needed.  The research team at 
Washington University is 
responsible for reporting all 
applicable events to 
[MANUFACTURER] as 
needed.  Unexpected fatal or life -
threatening suspected 
adverse reaction  Report no later than [ADDRESS_545109] be obtained  prior to 
implementing the change.  
 
  
 
Version 03/16/2020 – Amendment 13   Page 87 of 87 
  APPENDIX G: Washington University Serious Adverse Event Reporting Cover Sheet  
 
SAE COVER SHEET-  Secondary Site Assessment  
 
Washington University HRPO#:  Sponsor -Investigator:  
Subject Initials:   Subject ID:  
Treating MD:  Treating Site:  
EVENT TERM:  Event Start Date:  
EVENT GRADE:  Date of site’s first notification:  
 
Treating MD Event Assessment:  
 
 
Is this event possibly, probably, or definitely related study treatment? 
 
 yes    no 
 If yes, please list which drug (if more than one)______________________________  
       Explain ______________________________________________________________________ 
 
______________________________________________________________________________ 
 
  _________________________           ___________________________      _________________  
Physician’s Na me   Physician’s Signature   [CONTACT_1782]  
 
 